




**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03026953.4

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamtes
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 03026953.4
Demande no:

Anmeldetag:
Date of filing: 25.11.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER
WISSENSCHAFTEN E.V.

14195 Berlin
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

FKBP51 : A novel target for antidepressant therapy

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12Q1/68

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filling/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

EPO - Munich
33
25 Nov. 2003

New EP Patent Application
Max-Planck-Gesellschaft zur Förderung...
Our Ref.: H 2589 EP

FKBP51: A Novel Target for Antidepressant Therapy

The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to antidepressant therapy. Furthermore, a method of developing an anti-depressant drug, and pharmaceutical compositions are provided.

In this specification, a number of documents is cited. The disclosure of these documents, including manufacturer's manuals, is herewith incorporated by reference in its entirety.

National surveys in Germany and in the United States agree that depression and other affective disorders (e.g. anxiety disorders and bipolar disorder) are among the most common medical conditions worldwide with lifetime prevalence for major depression reaching up to 14%. Pharmacotherapy is an effective treatment of depression and since the serendipitous discovery of the first antidepressant drug imipramine, a number of antidepressant drugs are now available. So far, all commercially available antidepressant drugs share the same pharmacological principle of enhancing monoaminergic neurotransmission, even though this may be achieved through a variety of mechanisms. Despite intensive efforts in the development of antidepressant drugs, major breakthroughs have only been achieved on the side effect profile of these drugs. Even though antidepressants are the most effective treatment for depressive disorders, there is still substantial need for improvement. Adequate therapy response to a single antidepressant is only

observed in 40-60% of patients, even when given in sufficiently high dose for enough time. There is also a substantial lag between the onset of treatment and clinical improvement that can last up to several weeks, even if "therapeutical" plasma concentrations can now be reached in a shorter amount of time. Furthermore, there are a percentage of patients that develop therapy-resistant depression, unresponsive to multiple treatment trials.

Although antidepressant drugs elicit quite divergent immediate effects, it is hypothesized that they all target a common final signaling pathway. The hypothalamic-pituitary-adrenal (HPA) system is considered to play a central pathophysiological role in this disease, because this system is not only consistently dysregulated in patients suffering from major depression, but normalization of this dysregulation is a prerequisite for successful treatment¹. Currently used antidepressant drugs exert instant actions at various elements involved in monoaminergic neurotransmission². These trigger a cascade of events that ultimately lead to the resolution of the clinical symptoms of depression. A host of data implicates central and peripheral disturbances of stress hormone regulation in the pathogenesis of depression and normalization of these defects as a necessary predecessor of clinical response to medication^{3,4}. Central mechanisms for HPA-axis hyperactivity are an increased neurotransmission of the hypothalamic peptides corticotropin releasing hormone (CRH) and arginine vasopressin (AVP) that stimulate adrenocorticotropic hormone (ACTH) and cortisol release and an impaired negative feedback of this system due to glucocorticoid (GC) receptor (GR) insensitivity^{5,6,7,8}. Preclinical and clinical studies suggest that one mechanism of action of antidepressant drugs may be to restore negative HPA-axis feedback via the GR leading to a downregulation of the overexpressed peptides CRH and AVP^{9,10,11,12,13,14}. For proper functioning the GR, a ligand-activated transcription factor, depends on a large molecular complex that is necessary for proper receptor

REPRODUCED WITH THE PERMISSION OF THE AUTHOR

binding, FKBP51 is replaced by FKBP52, which then recruits dynein into the complex, allowing its nuclear translocation and transcriptional activity²⁰. A naturally occurring overexpression of FKBP51 appears to be the common cause of GR insensitivity in New world monkeys^{21,22,23,26}. Moreover, overexpression of human FKBP51²¹ *in vitro* clearly reduces hormone binding affinity and nuclear translocation of GR. Glucocorticoids induce FKBP51 mRNA expression via an ultra-short negative feedback loop for GR activity²⁴.

It is known that the response to antidepressant therapy varies significantly from patient to patient. So far, these variations can only be determined and analysed in a retrospective manner. However, it would be highly desirable to classify individuals and to predict their response to therapy in order to tailor treatment to the individual patient's specific needs. The technical problem underlying the present invention therefore was to provide methods of classifying individuals.

The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said individual for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In other words, said analyzing is performed *in vitro*. In an alternative embodiment, said analyzing is performed *ex vivo* or *in vivo*.

The term "classifying" refers to the assignment of individuals to two or more groups or classes. In other words, individuals, previously unclassified, get labelled by their respective class. The assigned class label may refer to parameters used for classification, e.g. polymorphisms and/or expression levels, or may refer to parameters not used for classification because their values are not known beforehand, e.g. fast or slow response to therapy. In the first case, class discovery methods, e.g. clustering may be applied, whereas in the second case predictive classification methods are used. Classification may be done manually by a trained person or by a computer program provided with the values of the parameters used

for class distinction. Patients have to give informed consent. Data have to be handled and kept secret in accordance with national laws.

The term "nucleotide polymorphism" refers to the occurrence of one or more different nucleotides or bases at a given location on a chromosome. Usually, polymorphisms are distinguished from mutations based on their prevalence. Sometimes a threshold of 1% prevalence in a population of individuals is considered for separating polymorphisms (more frequent) from mutations (less frequent). A single nucleotide polymorphism (SNP) is a polymorphism of a single nucleotide or base. The SNP database maintained at NCBI (<http://www.ncbi.nlm.nih.gov/SNP/>) divides SNPs into SNPs in the proximity of a known locus and such that are 5' further away than 2 kb from the most 5' feature of a gene and 3' further away than 500 bases from the most 3' feature of a gene. SNPs in the proximity of a known locus are further divided into SNPs occurring at an mRNA location and such that do not. SNPs occurring at an mRNA location comprise coding and non-coding SNPs.

In view of the evidence relating to nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 laid down in the present application, the inventors for the first time envisaged classifying individuals based on said polymorphisms.

Nucleotide polymorphisms may be associated or linked to a particular phenotype. Genetic screening exploits this association.

Genetic screening (also called genotyping or molecular screening), can be broadly defined as testing to determine if an individual has mutations, alleles or polymorphisms that either cause a specific phenotype or are "linked" to the mutation causing the phenotype. Linkage refers to the phenomenon that the DNA sequences which are close together in the genome have a tendency to be inherited together.

because, in a given population, they tend to either both occur together or else not occur at all in any particular member of the population. Indeed, where multiple polymorphisms in a given chromosomal region are found to be in linkage disequilibrium with one another, they define a quasi-stable genetic "haplotype", "haplotype block" or "LD block".

Location and size of haplotype blocks can be determined using computer programs, e.g. the program HaploBlockFinder²⁵. Figure 1 shows a linkage disequilibrium map of the FKBP51 region.

Furthermore, where a phenotype-causing polymorphism is found within or in linkage with a haplotype, one or more polymorphic alleles of the haplotype can be used as a diagnostic or prognostic indicator of the likelihood of developing a specific phenotype. Identification of a haplotype which spans or is linked to a phenotype-causing polymorphism, serves as a predictive measure of an individual's likelihood of exhibiting that phenotype-causing polymorphism. Importantly, such prognostic or diagnostic procedures can be utilized without necessitating the identification and isolation of the actual phenotype-causing molecule. This is significant because the precise determination of the molecular basis of the establishment of a specific phenotype can be difficult and laborious, especially in the case of multifactorial phenotype.

Surprisingly, it has been found in healthy individuals that nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 correlate with the expression level of FKBP51. Therefore, according to the invention, the expression level of FKBP51 may be determined instead of or in addition to said nucleotide polymorphisms for the purpose of classifying individuals.

As stated above, there is an unmet need for methods of classifying patients suffering from depression with regard to their response to therapy. Unexpectedly, nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 were found to correlate significantly with the response to antidepressant therapy.

Therefore, it is preferred in accordance with the present invention that said classifying consists of or comprises predicting the response to therapy of an individual, wherein said individual is a patient suffering from depression. The availability of information as to the expected response to therapy is of great advantage for the patient, as a rational choice of drug and/or a tailored therapy regimen minimize adverse side effects and ensure the fastest decline of the symptoms of the disease.

Figure 2 shows a plot of the significance of the association with response to antidepressant therapy of SNPs in or in the proximity of the FKBP51 locus investigated by the inventors.

"Therapy" refers in accordance with the present invention to treatment with antidepressant drugs. Most antidepressant drugs target the transport of the neurotransmitters serotonin and/or norepinephrine, or the activity of the enzyme monoamine oxidase. Common antidepressant drugs include: Selective serotonin-reuptake inhibitors (e.g., fluoxetine, paroxetine, sertraline; fluvoxamine), tricyclic antidepressants (e.g., amitriptyline, imipramine, desipramine, nortriptyline), monoamine oxidase inhibitors (e.g., phenelzine, isocarboxazid, tranylcypromine), and designer antidepressants such as mirtazapine, reboxetine, nefazodone. Benzodiazepines, or lithium carbonate may also be administered.

The inventors surprisingly found that elevated levels of FKBP51 correlate significantly with a faster response to therapy, i.e., the decline of symptoms of depression as determined by the Hamilton Depression Rating Scale (HAM-D) sets in earlier than in patients with lower levels of FKBP51. This observation is indeed unexpected, considering that transcriptional activity of GR heterocomplex requires that FKBP51 dissociates from the heterocomplex. The skilled person would expect that elevated levels of FKBP51 lead to an accumulation of the GR heterocomplex in the cytoplasm.

16201 PCT/US2006/032262 2010-03-09 10:46:20 2010-03-09 10:46:20
16201 PCT/US2006/032262 2010-03-09 10:46:20 2010-03-09 10:46:20

FKBP51 mRNA as a marker for the assessment of individual GC sensitivity, for the in vitro measurement of GC potency, and the in vivo determination of GC bioavailability. While Vermeer et al. describe an induced increase of FKBP51 expression, the present invention relates to elevated levels of FKBP51 expression associated with nucleotide polymorphisms. Vermeer et al. do not refer to any polymorphisms in the FKBP51 locus. Furthermore, Vermeer et al. do not refer to any implications of their observations for the field of depression therapy.

Also reference 1 (Holsboer, 2000) discusses the implications of an altered FKBP51 level for corticosteroid signaling. According to Holsboer, ligand-bound GR associates with other proteins comprising heat shock proteins and immunophilins, specifically FKBP51 or FKBP52. An elevated FKBP51 level is discussed in relation to excessively high cortisol levels in squirrel monkeys²⁸, whereby it is speculated that the elevated FKBP51 level serves for compensating the notoriously high cortisol levels in squirrel monkeys.

Holsboer furthermore discusses possible causes of inherited glucocorticoid resistance, viz. a polymorphism in the GR gene or other alterations in genes, whose products are involved in glucocorticoid signaling. However, Holsboer does not designate any specific protein involved in glucocorticoid signaling.

The application of genotyping in the field of pharmacology gave rise to the fields of pharmacogenetics and, more recently, pharmacogenomics, the latter being used to denote studies correlating drug response with the analysis of multiple genes, e.g. their expression and/or polymorphisms or mutations in said genes. It is envisaged to stratify the population such that groups of individuals are obtained which receive tailored treatments. In order to get approval for tailored drugs and/or treatment regimens, the stratification of the population has to be extended to clinical trials.

Therefore, in a preferred embodiment, classifying according to the present invention consists of or comprises selecting an individual for a clinical trial. Individuals selected for clinical trials in accordance with the present invention may comprise healthy individuals and/or patients suffering from depression.

There are several published patent applications in the field of pharmacogenomics, that describe the use of gene sequence variations including SNPs (WO 00/50639, WO 99/64626) or expression profiling on a large scale for evaluating antidepressant and other drug response in patients. They give detailed technical descriptions on how to use SNPs to assess drug response. However, these documents neither anticipate nor suggest to investigate polymorphisms in the FKBP51 locus or FKBP51 expression levels.

It has been found by the inventors that nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 correlate with the number of a patient's previous episodes of depression. Therefore, said polymorphisms and/or the expression level of FKBP51 can be used as (a) prognostic marker/s for an elevated number of episodes of depression.

Accordingly, in a further preferred embodiment, classifying according to the present invention consists of or comprises predicting the predisposition of an individual for an elevated number of episodes of depression, wherein said individual is a patient suffering from depression.

In a preferred embodiment, the nucleic acid to be analyzed is genomic DNA (gDNA).

In a more preferred embodiment, the haplotype block comprises at least one SNP selected from the group consisting of rs4713916, rs3800372, rs1360780 and rs3800373. According to this embodiment, the identification and analysis of any nucleotide polymorphism in said haplotype block is envisaged.

The identifiers recited above permit retrieval of sequence and other information for the respective SNP in the SNP database maintained at the NCBI (<http://www.ncbi.nlm.nih.gov/SNP/>).

consisting of rs4713916, rs3800372, rs1360780 and rs3800373.

These four SNPs are most significantly associated with improved response to antidepressant treatment. The following table summarises the position of these SNPs on chromosome 6, the region of the FKBP51 locus containing the SNP, nucleotide changes for each genotype, heterozygote frequency and the p-value for an association with fast response to an antidepressant drug.

Table 1

| SNP | Position On Chr 6 | type | Nucleotide change | Heterozygote frequency | p-value |
|-----------|-------------------|-----------------|-------------------|------------------------|----------------------|
| rs4713916 | 35716838 | Promoter region | G/A | 36.6% | 5.5×10^{-5} |
| rs3800372 | 35702100 | Intron 1 | T/C | 33.0% | 5.5×10^{-6} |
| rs1360780 | 35654426 | Intron 2 | C/T | 40.1% | 1.2×10^{-4} |
| rs3800373 | 35589331 | 3'UTR | A/C | 33.0% | 2.8×10^{-5} |

Following the identification of individuals homozygous for the AA allele of rs4713916, or the CC allele of rs3800372, or the TT allele of rs1360780, or the CC allele of rs3800373, or patients with an increase in the expression levels of FKBP51, a normal prudent physician would recommend prescription or administration of an antidepressant drug. Administration and dosage of antidepressant drugs can vary between patients and are well known in the medical art, see, for example Benkert and Hippius, "Kompendium der Psychiatrischen Pharmakotherapie", Springer Verlag Publishing, 2000; Albers, "Handbook of Psychiatric Drugs: 2001-2002 Edition", Current Clinical Strategies Publishing, 2000. Preferred examples include between 5 mg and 80 mg per day, preferably 20 mg, fluoxetine; between 5 mg and 50 mg per day, preferably 20 mg, paroxetine; between 5 mg and 200 mg per day, preferably 50 mg, sertraline; between 5 mg and 300 mg per day, preferably 100 mg, fluvoxamine; between 5 mg and 100 mg per day, preferably 30 mg, mirtazapine; between 4 mg and 50 mg, preferably 8 mg, reboxetine; between 5 mg and 600 mg per day, preferably 200 mg, nefazodone; between 450 mg and 1800 mg per day, preferably 900 mg, lithium carbonate.

Furthermore, the SNPs listed in Table 1 correlate with the number of previous episodes of depression. This is exemplified by the data shown in Figures 5 (rs1360780) and 7 (rs3800372).

Several methods of analyzing a nucleic acid for nucleotide polymorphisms are known in the art. Accordingly, in a preferred embodiment, analyzing the nucleic acid by the method of the invention comprises (a) a primer extension assay; (b) a differential hybridization assay; and/or (c) an assay which detects allele-specific enzyme cleavage.

The underlying principles and the use of said assays has been described in an article of Asil Memisoglu (www.thebiotechclub.org/industry/emerging/pharmacogenomics.php). Examples for said assays are known by a person skilled in the art.

In a more preferred embodiment, the method according to the invention comprises, prior to analyzing, amplification of at least a portion of said haplotype block. Preferably, said amplification is effected by or said amplification is the polymerase chain reaction (PCR). The principles of and procedures to perform PCR are known in the art.

In a more preferred embodiment, said amplification reaction uses primers which hybridize specifically with a portion of said haplotype block. Means of ensuring specificity of hybridization according to the present invention are known in the art and include stringent hybridization conditions. The term "stringent hybridization conditions", as used in the description of the present invention, is well known to the skilled artisan. Appropriate stringent hybridization conditions for each sequence may be established by a person skilled in the art on well-known parameters such as temperature, composition of the nucleic acid molecules, salt conditions etc.; see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual"; CSH Press,

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | 433 | 434 | 435 | 436 | 437 | 438 | 439 | 440 | 441 | 442 | 443 | 444 | 445 | 446 | 447 | 448 | 449 | 450 | 451 | 452 | 453 | 454 | 455 | 456 | 457 | 458 | 459 | 460 | 461 | 462 | 463 | 464 | 465 | 466 | 467 | 468 | 469 | 470 | 471 | 472 | 473 | 474 | 475 | 476 | 477 | 478 | 479 | 480 | 481 | 482 | 483 | 484 | 485 | 486 | 487 | 488 | 489 | 490 | 491 | 492 | 493 | 494 | 495 | 496 | 497 | 498 | 499 | 500 | 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 | 511 | 512 | 513 | 514 | 515 | 516 | 517 | 518 | 519 | 520 | 521 | 522 | 523 | 524 | 525 | 526 | 527 | 528 | 529 | 530 | 531 | 532 | 533 | 534 | 535 | 536 | 537 | 538 | 539 | 540 | 541 | 542 | 543 | 544 | 545 | 546 | 547 | 548 | 549 | 550 | 551 | 552 | 553 | 554 | 555 | 556 | 557 | 558 | 559 | 560 | 561 | 562 | 563 | 564 | 565 | 566 | 567 | 568 | 569 | 570 | 571 | 572 | 573 | 574 | 575 | 576 | 577 | 578 | 579 | 580 | 581 | 582 | 583 | 584 | 585 | 586 | 587 | 588 | 589 | 590 | 591 | 592 | 593 | 594 | 595 | 596 | 597 | 598 | 599 | 600 | 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 | 609 | 610 | 611 | 612 | 613 | 614 | 615 | 616 | 617 | 618 | 619 | 620 | 621 | 622 | 623 | 624 | 625 | 626 | 627 | 628 | 629 | 630 | 631 | 632 | 633 | 634 | 635 | 636 | 637 | 638 | 639 | 640 | 641 | 642 | 643 | 644 | 645 | 646 | 647 | 648 | 649 | 650 | 651 | 652 | 653 | 654 | 655 | 656 | 657 | 658 | 659 | 660 | 661 | 662 | 663 | 664 | 665 | 666 | 667 | 668 | 669 | 670 | 671 | 672 | 673 | 674 | 675 | 676 | 677 | 678 | 679 | 680 | 681 | 682 | 683 | 684 | 685 | 686 | 687 | 688 | 689 | 690 | 691 | 692 | 693 | 694 | 695 | 696 | 697 | 698 | 699 | 700 | 701 | 702 | 703 | 704 | 705 | 706 | 707 | 708 | 709 | 710 | 711 | 712 | 713 | 714 | 715 | 716 | 717 | 718 | 719 | 720 | 721 | 722 | 723 | 724 | 725 | 726 | 727 | 728 | 729 | 730 | 731 | 732 | 733 | 734 | 735 | 736 | 737 | 738 | 739 | 740 | 741 | 742 | 743 | 744 | 745 | 746 | 747 | 748 | 749 | 750 | 751 | 752 | 753 | 754 | 755 | 756 | 757 | 758 | 759 | 760 | 761 | 762 | 763 | 764 | 765 | 766 | 767 | 768 | 769 | 770 | 771 | 772 | 773 | 774 | 775 | 776 | 777 | 778 | 779 | 780 | 781 | 782 | 783 | 784 | 785 | 786 | 787 | 788 | 789 | 790 | 791 | 792 | 793 | 794 | 795 | 796 | 797 | 798 | 799 | 800 | 801 | 802 | 803 | 804 | 805 | 806 | 807 | 808 | 809 | 810 | 811 | 812 | 813 | 814 | 815 | 816 | 817 | 818 | 819 | 820 | 821 | 822 | 823 | 824 | 825 | 826 | 827 | 828 | 829 | 830 | 831 | 832 | 833 | 834 | 835 | 836 | 837 | 838 | 839 | 840 | 841 | 842 | 843 | 844 | 845 | 846 | 847 | 848 | 849 | 850 | 851 | 852 | 853 | 854 | 855 | 856 | 857 | 858 | 859 | 860 | 861 | 862 | 863 | 864 | 865 | 866 | 867 | 868 | 869 | 870 | 871 | 872 | 873 | 874 | 875 | 876 | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | 887 | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | 898 | 899 | 900 | 901 | 902 | 903 | 904 | 905 | 906 | 907 | 908 | 909 | 910 | 911 | 912 | 913 | 914 | 915 | 916 | 917 | 918 | 919 | 920 | 921 | 922 | 923 | 924 | 925 | 926 | 927 | 928 | 929 | 930 | 931 | 932 | 933 | 934 | 935 | 936 | 937 | 938 | 939 | 940 | 941 | 942 | 943 | 944 | 945 | 946 | 947 | 948 | 949 | 950 | 951 | 952 | 953 | 954 | 955 | 956 | 957 | 958 | 959 | 960 | 961 | 962 | 963 | 964 | 965 | 966 | 967 | 968 | 969 | 970 | 971 | 972 | 973 | 974 | 975 | 976 | 977 | 978 | 979 | 980 | 981 | 982 | 983 | 984 | 985 | 986 | 987 | 988 | 989 | 990 | 991 | 992 | 993 | 994 | 995 | 996 | 997 | 998 | 999 | 1000 | 1001 | 1002 | 1003 | 1004 | 1005 | 1006 | 1007 | 1008 | 1009 | 1010 | 1011 | 1012 | 1013 | 1014 | 1015 | 1016 | 1017 | 1018 | 1019 | 1020 | 1021 | 1022 | 1023 | 1024 | 1025 | 1026 | 1027 | 1028 | 1029 | 1030 | 1031 | 1032 | 1033 | 1034 | 1035 | 1036 | 1037 | 1038 | 1039 | 1040 | 1041 | 1042 | 1043 | 1044 | 1045 | 1046 | 1047 | 1048 | 1049 | 1050 | 1051 | 1052 | 1053 | 1054 | 1055 | 1056 | 1057 | 1058 | 1059 | 1060 | 1061 | 1062 | 1063 | 1064 | 1065 | 1066 | 1067 | 1068 | 1069 | 1070 | 1071 | 1072 | 1073 | 1074 | 1075 | 1076 | 1077 | 1078 | 1079 | 1080 | 1081 | 1082 | 1083 | 1084 | 1085 | 1086 | 1087 | 1088 | 1089 | 1090 | 1091 | 1092 | 1093 | 1094 | 1095 | 1096 | 1097 | 1098 | 1099 | 1100 | 1101 | 1102 | 1103 | 1104 | 1105 | 1106 | 1107 | 1108 | 1109 | 1110 | 1111 | 1112 | 1113 | 1114 | 1115 | 1116 | 1117 | 1118 | 1119 | 1120 | 1121 | 1122 | 1123 | 1124 | 1125 | 1126 | 1127 | 1128 | 1129 | 1130 | 1131 | 1132 | 1133 | 1134 | 1135 | 1136 | 1137 | 1138 | 1139 | 1140 | 1141 | 1142 | 1143 | 1144 | 1145 | 1146 | 1147 | 1148 | 1149 | 1150 | 1151 | 1152 | 1153 | 1154 | 1155 | 1156 | 1157 | 1158 | 1159 | 1160 | 1161 | 1162 | 1163 | 1164 | 1165 | 1166 | 1167 | 1168 | 1169 | 1170 | 1171 | 1172 | 1173 | 1174 | 1175 | 1176 | 1177 | 1178 | 1179 | 1180 | 1181 | 1182 | 1183 | 1184 | 1185 | 1186 | 1187 | 1188 | 1189 | 1190 | 1191 | 1192 | 1193 | 1194 | 1195 | 1196 | 1197 | 1198 | 1199 | 1200 | 1201 | 1202 | 1203 | 1204 | 1205 | 1206 | 1207 | 1208 | 1209 | 1210 | 1211 | 1212 | 1213 | 1214 | 1215 | 1216 | 1217 | 1218 | 1219 | 1220 | 1221 | 1222 | 1223 | 1224 | 1225 | 1226 | 1227 | 1228 | 1229 | 1230 | 1231 | 1232 | 1233 | 1234 | 1235 | 1236 | 1237 | 1238 | 1239 | 1240 | 1241 | 1242 | 1243 | 1244 | 1245 | 1246 | 1247 | 1248 | 1249 | 1250 | 1251 | 1252 | 1253 | 1254 | 1255 | 1256 | 1257 | 1258 | 1259 | 1260 | 1261 | 1262 | 1263 | 1264 | 1265 | 1266 | 1267 | 1268 | 1269 | 1270 | 1271 | 1272 | 1273 | 1274 | 1275 | 1276 | 1277 | 1278 | 1279 | 1280 | 1281 | 1282 | 1283 | 1284 | 1285 | 1286 | 1287 | 1288 | 1289 | 1290 | 1291 | 1292 | 1293 | 1294 | 1295 | 1296 | 1297 | 1298 | 1299 | 1300 | 1301 | 1302 | 1303 | 1304 | 1305 | 1306 | 1307 | 1308 | 1309 | 1310 | 1311 | 1312 | 1313 | 1314 | 1315 | 1316 | 1317 | 1318 | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°. Other stringent hybridization conditions are for example 0.2 x SSC (0.03 M NaCl, 0.003M Natriumcitrat, pH 7) at 65°C.

In a preferred embodiment, the primers to be used for said amplification reaction have the sequence as set forth in SEQ ID NOs: 1 and 2; 3 and 4; 5 and 6; or 7 and 8 and disclosed in the following table.

Table 2

| SNP-ID | sense | antisense |
|-----------|--|---|
| rs4713916 | ACGTTGGATGTATCTGGCAACCCTAACCTC (SEQ ID NO: 1) | ACGTTGGATGCCTAACGAGATAAGTGAGGAG (SEQ ID NO: 2) |
| rs3800372 | ACGTTGGATGAACACCAAGAGAAGCAGCTC (SEQ ID NO: 3) | ACGTTGGATGCTATCCACCTCCTCCATAAG (SEQ ID NO: 4) |
| rs1360780 | ACGTTGGATGAAGAGATCCAGGCACAGAAG (SEQ ID NO: 5) | ACGTTGGATGTGCCAGCAGTAGCAAGTAAG (SEQ ID NO: 6) |
| rs3800373 | ACGTTGGATGAAACCCCTAGTGTAGAAGAG (SEQ ID NO: 7) | ACGTTGGATGTTTACACTCCTCTATCATGC (SEQ ID NO: 8) |

In the primer extension assay according to the invention the target sequence is annealed to a primer complementary to the region adjacent to the SNP site. Dideoxyribonucleotides (ddNTPS) and DNA polymerase are added to the mixture and the primer is extended by a single nucleotide. The single nucleotide added is dependent on the allele of the amplified DNA. Primer extension biochemistry can be coupled with a variety of detection schemes, comprising fluorescence, fluorescence polarization (FP), luminescence and mass spectrometry (MS).

Accordingly, in a preferred embodiment of the method of the invention, the primer extension assay uses a primer which hybridizes specifically with a portion of said haplotype block which is adjacent to a polymorphism. The following table discloses the primers used for genotyping using single-base extension assays.

Table 3

| SNP-ID | Extension primer | |
|-----------|--------------------------|------------------|
| rs4713916 | GACTCCTACATTTCTCT | (SEQ ID NO : 9) |
| rs3800372 | GAAGCAGCTCCCTTCTAGA | (SEQ ID NO : 10) |
| rs1360780 | GGCTTTCACATAAGCAAAGTTA | (SEQ ID NO : 11) |
| rs3800373 | AAGAGCAACTATTTATTTGTCAAC | (SEQ ID NO : 12) |

Therefore, in a preferred embodiment of the method of the invention, the primer to be used for said primer extension assay has the sequence as set forth in SEQ ID NO: 9, 10, 11 or 12.

Further methods of analyzing a nucleic acid for the occurrence of polymorphisms are differential hybridization and allele-specific enzyme cleavage. The latter is also referred to as **Restriction Fragment Length Polymorphism (RFLP)**.

Restriction Fragment Length Polymorphism (RFLP) is a technique in which species, strains, or, as envisaged by the inventors, polymorphic alleles may be differentiated by analysis of patterns derived from cleavage of their DNA. If two organisms differ in the distance between sites of cleavage of a particular restriction endonuclease, the length of the fragments produced will differ when the DNA is digested with a restriction enzyme.

In a preferred embodiment, the differential hybridization assay according to the invention or said assay detecting allele-specific enzyme cleavage according to the invention uses probes which hybridize specifically with a portion of said haplotype block which comprises a polymorphism. The detection of allele-specific enzyme

In a more preferred embodiment, said probes have the sequence as set forth in SEQ ID NO: 13 and 14; 15 and 16; 17 and 18; or 19 and 20. The sequences are shown in the table below.

Table 4

| SNP | Column A Probe for allele associated with improved response when present in a homozygous state | Column B Probe for allele associated with inferior response when present in a patient |
|-----------|---|--|
| rs4713916 | ATTTTCCTCTATCTGGTCCA (SEQ ID NO: 13) | ATTTTCCTCTGTCTGGTCCA (SEQ ID NO: 14) |
| rs3800372 | TAAAGTAATTCTCTAAAGGGA (SEQ ID NO: 15) | TAAAGTAATTCTCTAAAGGGA (SEQ ID NO: 16) |
| rs1360780 | AGCAAAGTTATACAAAAACAAA (SEQ ID NO: 17) | AGCAAAGTTACACAAAAACAAA (SEQ ID NO: 18) |
| rs3800373 | ATTTGTCAACCCCTACAGATTT (SEQ ID NO: 19) | ATTTGTCAACACTACAGATTT (SEQ ID NO: 20) |

Each of these probes recognizes one of the two alleles at the respective SNPs only. For example, in a hybridization experiment for the rs4713916 SNP, a hybridization signal with the probe in column A and no signal with the probe in column B would be indicative of a person with improved response to therapy, whilst a signal with both probes and with only the probe from column B would be indicative of inferior response. The same also applies to the other SNPs (rs3800372, rs1360780, and rs3800373).

In a more preferred embodiment, the probes used for the differential hybridization assay are immobilized on a supporting material. Probe sets, immobilized on a filter or solid support and arranged in arrayed form, are generally referred to as microarrays or DNA chips.

As described above, SNPs which correlate with response to therapy in patients suffering from depression, correlate also with FKBP51 expression levels. The latter correlation has been observed in healthy individuals. Therefore, the administration of antidepressant drugs does not account for the observed differences in FKBP51 expression level. Without being bound by a specific theory, it is assumed that SNPs in the FKBP51 locus are responsible for different FKBP51 expression levels. Therefore, the use of FKBP51 expression levels for classification and prognostic

methods according to the invention is envisaged.

In a preferred embodiment, the FKBP51 expression level to be determined is the mRNA expression level. Methods for the determination of mRNA expression levels are known in the art and comprise Real Time RT-PCR, Northern blotting and hybridization on microarrays or DNA chips equipped with one or more probes or probe sets specific for FKBP51 transcripts.

In a further preferred embodiment, the expression level to be determined is the protein expression level. The skilled person is aware of methods for the quantitation of proteins. Amounts of purified protein in solution can be determined by physical methods, e.g. photometry. Methods of quantifying a particular protein in a mixture rely on specific binding, e.g. of antibodies. Specific detection and quantitation methods exploiting the specificity of antibodies comprise immunohistochemistry (*in situ*) and surface plasmon resonance. Western blotting combines separation of a mixture of proteins by electrophoresis and specific detection with antibodies. Example 1, sub-heading "Quantification of FKBP51 protein levels in lymphocytes", provides an example of how protein expression levels can be determined according to the invention. Example 4 and Figure 9 present and discuss results obtained by Western blotting and their implications for the methods according to the invention.

In a preferred embodiment, the method of selecting an individual for a clinical trial according to the invention, further comprises the steps: (a) identifying a compound modulating the activity of FKBP51; and optionally (b) optimizing the pharmacological properties of the compound identified in (a); and (c) performing said clinical trials; wherein said clinical trials are clinical trials of the compound identified in (a) or optimized in (b). In this embodiment, the method of the invention may be used for the development of an antidepressant drug.

activator of FKBP51.

In a more preferred embodiment, the compound modulating the activity of FKBP51 increases the expression of FKBP51. The screen described below exemplifies the method for the identification of such compounds.

Screen for compounds that alter the promoter activity of FKBP51

The screen may employ any of the assays described below.

Reporter gene assays employing transient transfection into various cells from yeast to mammals is a standard procedure. For FKBP51, the regulatory regions, i.e. gene promoter and enhancer have to be cloned upstream of the structural part of a gene encoding for a reporter (cf. e.g. Mühlhardt, Der Experimentator: Molekularbiologie, Gustav Fischer Verlag 1999), for example, β -galactosidase, firefly luciferase, renilla luciferase, a fluorescing protein (e.g. GFP, EGFP, EYFP etc.), human growth hormone, CAT (chloramphenicolacetyltransferase), TAT (tyrosylaminotransferase), alkaline phosphatase including SEAP, and peroxidase. Suitable eukaryotic cell lines include immortalized tumour cell lines, listed for example in the catalogues of ATCC and ETCC, in particular the cell lines HeLa, HEK, L929, NIH3T3, COS1, COS7, HepG2, H4-II-E-C3, Saos, K562, SK-N-MC, HT22, CV-1 preferably SK-N-MC or HEK cells. As an alternative to transient transfection assays, an in vitro transcription/translation system may be adapted, or stably transfected cell lines may be used accordingly. A number of methods are established to generate cell lines stably transfected with a reporter gene plasmid.

All assays have to be performed in the presence or absence of test compounds that comprise small molecules, peptides, aptamers and antibodies or fragments or derivatives thereof. An increase in expression of FKBP51 in the presence of a test compound identifies the compound as a hit.

This screen can be extended to modulators of the expression of FKBP52 by replacing the FKBP51 nucleic acid or amino acid sequence with the FKBP52 nucleic acid or amino acid sequence.

In a further preferred embodiment, the compound modulating the activity of FKBP51 enhances function and/or stability of FKBP51. The screen described below exemplifies the method for the identification of such compounds.

Screen for compounds that bind to FKBP51 and change its function or stability

This screen is designed to first identify compounds that bind to FKBP51 and subsequently determine FKBP51-binding compounds that in addition have functional effects.

For the purpose of identifying FKBP51-binding compounds, for example a phage display library may be used. While using a phage display library allows to screen peptide compounds, the Biacore 3000 system is suitable for detection of any compound that binds to FKBP51 larger than 180 dalton. The Biacore system requires purified, human FKBP51, which can be from any source, preferably expressed in a bacterial expression system, preferably as a His-tagged protein. Purification of His-tagged protein is an established, standardized procedure and can be performed according to the manufacturers recommendation, e.g. Qiagen or Invitrogen. Any expression vector for recombinant proteins in bacteria can be used, preferably one that provides inducible expression, preferably the vector series pProExHTa (Invitrogen).

Any technique that attaches the purified FKBP51 protein to the Biacore sensor chip surface may be used. In particular, the use of NTA sensor chips is suitable for the His-tagged version of the recombinant FKBP51. Automatic screening of a large number of compounds can be performed according to established protocols by the Biacore manufacturer. Compounds that bind to FKBP51 will then be subjected to subsequent analyses to identify those with an effect on protein stability of FKBP51, on hormone binding of GR or on GR-dependent transcription.

western blotting techniques on an Imaging System, preferably an imaging station like Kodak 440CF.

To determine hormone binding affinity, a number of different protocols are available. Binding affinity can be measured in tissues, in cell extracts, or in a partially purified extract of the glucocorticoid receptor, which needs to be supplemented with recombinant FKBP51. A recombinant, partially purified human glucocorticoid receptor expressed in the Baculovirus system is available from Panvera.

Assays for determining glucocorticoid receptor-dependent gene transcription are well known in the art, see for example Herr et al., Mol.Pharmacol. 57 (2000), 732-737; Hollenberg et al., Cancer Res. 49 (1989), 2292s-2294s; Kullmann et al., J.Biol.Chem. 273 (1998), 14620-14625; Rupprecht et al., Eur. J. Pharmacol. 247 (1993), 145-154. These assays may be performed using one of the transient transfection methods or in stably transfected cell lines.

This screen can be extended to FKBP52 binders and modulators by replacing the FKBP51 nucleic acid or amino acid sequence with the FKBP52 nucleic acid or amino acid sequence.

Methods for the optimization of the pharmacological properties of compounds identified in screens, generally referred to as lead compounds, are known in the art and comprise a method of modifying a compound identified as a lead compound to achieve: (i) modified site of action, spectrum of activity, organ specificity, and/or (ii) improved potency, and/or (iii) decreased toxicity (improved therapeutic index), and/or (iv) decreased side effects, and/or (v) modified onset of therapeutic action, duration of effect, and/or (vi) modified pharmacokinetic parameters (resorption, distribution, metabolism and excretion), and/or (vii) modified physico-chemical parameters (solubility, hygroscopicity, color, taste, odor, stability, state), and/or (viii) improved general specificity, organ/tissue specificity, and/or (ix) optimized application form and route by (i) esterification of carboxyl groups, or (ii) esterification of hydroxyl groups with carbon acids, or (iii) esterification of hydroxyl groups to, e.g. phosphates, pyrophosphates or sulfates or hemi succinates, or (iv) formation of pharmaceutically

acceptable salts, or (v) formation of pharmaceutically acceptable complexes, or (vi) synthesis of pharmacologically active polymers, or (vii) introduction of hydrophilic moieties, or (viii) introduction/exchange of substituents on aromates or side chains, change of substituent pattern, or (ix) modification by introduction of isosteric or bioisosteric moieties, or (x) synthesis of homologous compounds, or (xi) introduction of branched side chains, or (xii) conversion of alkyl substituents to cyclic analogues, or (xiii) derivatisation of hydroxyl group to ketales, acetals, or (xiv) N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannich bases, imines, or (xvi) transformation of ketones or aldehydes to Schiff's bases, oximes, acetals, ketales, enolesters, oxazolidines, thiazolidines or combinations thereof; said method optionally further comprising the steps of the above described methods.

The various steps recited above are generally known in the art. They include or rely on quantitative structure-action relationship (QSAR) analyses (Kubinyi, "Hausch-Analysis and Related Approaches", VCH Verlag, Weinheim, 1992), combinatorial biochemistry, classical chemistry and others (see, for example, Holzgrabe and Bechtold, Deutsche Apotheker Zeitung 140(8), 813-823, 2000).

Clinical trials according to the invention can for example be performed as described in the following protocol.

Protocols for clinical trials

Response to treatment by an antidepressant, time until response (i.e. latency) to an antidepressant, or patient outcome to an antidepressant treatment protocol can be predicted by determining in patients the presence of at least one of the FKBP51 SNPs disclosed in Table 1. Accordingly, an individual homozygous for the AA allele of rs4713916, or the CC allele of rs3800372, or the TT allele of rs1360780, or the CC allele of rs3800373, or with elevated FKBP51 expression levels would have an

FKBP51 expression would have an inferior, or slower response to an antidepressant drug. The various alleles are summarised in the following table.

Table 5

| SNP | Column A Allele associated with improved response | Column B Alleles associated with inferior response |
|-----------|---|--|
| rs4713916 | AA | GG or AG |
| rs3800372 | CC | TT or TC |
| rs1360780 | TT | CC or CT |
| rs3800373 | CC | AA or AC |

In a clinical trial for a new antidepressant drugs, patients would be grouped or selected according to the presence of one or more of the alleles found in column A. In addition, patients could be selected according to elevated FKBP51 levels. Such patients would then be enrolled into a clinical trial for testing the efficacy of a new antidepressant drug where the endpoint would be improvement in the Hamilton Depression Rating score, dexamethasone suppression test, or combined dexamethasone - corticotropin releasing hormone test. Results obtained with this group of patients could be compared to a second group of patients which possess one or more of the alleles found in column B or a group of patients with low FKBP51 expression.

In a more preferred embodiment, the method of classifying patients suffering from depression further comprises the step of treating said patient with an antidepressant.

In view of the favourable response to therapy associated with elevated levels of FKBP51, the invention also provides a pharmaceutical composition comprising (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451; (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451; and/or (c) a polypeptide encoded by the nucleic acid of (a) or (b).

Said nucleic acids are provided in a formulation and to be administered via a route which ensures their expression.

Preferably, said hybridizing occurs under stringent conditions.

SwissProt (<http://us.expasy.org/>) is a manually curated database of annotated protein sequences. The recited identifier (Q13451) refers to the SwissProt entry for human FK506-binding protein 51 (FKBP51), sometimes also referred to as FKBP5, FKBP54 or AIG6. FKBP51 acts as a peptidyl-prolyl cis-trans isomerase (rotamase).

The invention also relates to the use of (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451; (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451; (c) a polypeptide encoded by the nucleic acid of (a) or (b); (d) an activator of the expression of the polypeptide with the sequence of SwissProt accession number Q13451; and/or (e) an activator of the polypeptide with the sequence of SwissProt accession number Q13451 for the manufacture of a pharmaceutical composition for the treatment of depression. Said activator of expression can be obtained by the above described screen for compounds that alter the promoter activity of FKBP51. Said activator of the polypeptide can be identified by the above described screen for compounds that bind FKBP51 and change its function or stability.

Furthermore, the invention provides a method of treating depression comprising the administration of (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451; (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451; (c) a polypeptide encoded by the nucleic acid of (a) or (b); (d) an activator of the expression of the polypeptide with the sequence of SwissProt accession number Q13451; and/or (e) an activator of the polypeptide with the sequence of SwissProt accession number Q13451 for the manufacture of a pharmaceutical composition for the treatment of depression.

depression.

Recent studies have shown that FKBP51 and FKBP52 are physiologically relevant regulators of glucocorticoid receptor (GR) sensitivity. In the absence of steroids, FKBP51 interacts with the GR complex to retain it in the cytoplasm where it is inactive. Upon steroid binding, FKBP51 is replaced by FKBP52 which results in a recruitment of dynein into the GR complex, allowing nuclear translocation of the complex and transcriptional activity of the glucocorticoid receptor (Davies et al., J. Biol. Chem. 227 (2002), 4597-4600).

Thus, inhibitors of FKBP52 may have antidepressant effects by allowing FKBP51 to remain in contact with the GR complex and keeping the glucocorticoid receptor in an cytoplasmic inactive form despite steroid binding. The term "inhibitor of FKBP52" refers to substances inhibiting the biochemical or catalytic activity and/or the biological activity of FKBP52. The latter class of substances comprises compounds interfering with the interaction between FKBP52 and its interaction partners. Said interaction partners comprise components of the GR complex, including heat shock proteins such as Hsp90.

There are several examples of known or recognised FKBP52 inhibitors described in the art. Furthermore, inhibitors of immunophilins (or pepidyl-prolyl cis-transisomerases or rotamases) in general or of any specific immunophilin other than FKBP52 is a potential inhibitor of FKBP52. Whether such substance does inhibit FKBP52 can be assayed with the screens or assays described above.

A screening method to identify inhibitors of FKBP52 binding to partner proteins such as Hsp90 can be performed using bioluminescence resonance energy transfer (BRET). Briefly, the FKBP52 protein is fused to Renilla luciferase, whereas the Hsp90 protein is fused to a fluorescent protein, for example the yellow fluorescent protein (YFP). The emission of the luciferase signal is detected following addition of its substrate coelenterazine. When FKBP52 binds to Hsp90, a resonance energy transfer occurs between the luciferase and the YFP resulting in the detection of both the luciferase and the YFP signals. An inhibitor compound preventing binding of FKBP52 to Hsp90 would result in the emission of the luciferase signal only. The use

of BRET for drug screening is well known in the art, see for example Xu, Y. et al. (1999) A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc. Natl. Acad. Sci. U. S. A. 96: 151-156; Boute et al. (2002) The use of resonance energy transfer in high-throughput screening: BRET versus FRET. Trends Pharmacol. Sci. 23:351-354.

Identification of inhibitors of FKBP52 protein binding can also be done using the CheckMateTM Mammalian Two-Hybrid System from Promega or fluorescence resonance energy transfer (FRET). Such methods are well known in the art, see for example Serebriiskii et al. (2002) Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res. 12:1785-1791; Bergendahl et al. (2003) Luminescence resonance energy transfer-based high-throughput screening assay for inhibitors of essential protein-protein interactions in bacterial RNA polymerase. Appl. Environ. Microbiol. 69:1492-1498.

International Patent Applications WO 98/13343, WO 98/13355, WO 98/20891, WO 98/20892 and WO 98/20893 describe various pyrrolidine, piperidine and homopiperidine derivatives having an acyl, amide, oxanyl, or similar linking group, at the 1-position of the heterocycle.

US 5,721,256 describes various pyrrolidine, piperidine and homopiperidine derivatives having an SO₂ linking group at the 1-position of the heterocycle.

US 6,166,011 and US 6,509,464 disclose compounds that inhibit FKBP12 and FKBP52 without inhibiting the protein phosphatase calcineurin and therefore lack any significant immunosuppressive activity.

WO 99/21552 discloses an FKBP52 antibody and geldanamycin derivatives that can disrupt and inhibit the association between FKBP52 and Hsp90.

The present invention provides a pharmaceutical composition containing a recognised inhibitor of FKBP52.

treatment of depression. Suitable geldanamycin derivatives or analogs can be identified by the screens described above.

In a preferred embodiment, said inhibitor is an antibody or an aptamer specifically recognizing FKBP52 or a fragment or epitope thereof. Said antibody may be a monoclonal or a polyclonal antibody.

A more preferred embodiment of the invention relates to an antibody which is a monoclonal antibody.

Said antibody, which is monoclonal antibody, polyclonal antibody, single chain antibody, or fragment thereof that specifically binds FKBP52 also includes a bispecific antibody, synthetic antibody, antibody fragment, such as Fab, a F(ab₂)', Fv or scFv fragments etc., or a chemically modified derivative of any of these (all comprised by the term "antibody"). Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, *Nature* 256 (1975), 495, and Galfré, *Meth. Enzymol.* 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals with modifications developed by the art. Furthermore, antibodies or fragments thereof to the FKBP52 can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. When derivatives of said antibodies are obtained by the phage display technique, surface plasmon resonance as employed in the BIACore system can be used to increase the efficiency of phage antibodies which bind to an epitope of FKBP52 (Schier, *Human Antibodies Hybridomas* 7 (1996), 97-105; Malmborg, *J. Immunol. Methods* 183 (1995), 7-13). The production of chimeric antibodies is described, for example, in WO89/09622. A further source of antibodies to be utilized in accordance with the present invention are so-called xenogenic antibodies. The general principle for the production of xenogenic antibodies such as human antibodies in mice is described in, e.g., WO 91/10741, WO 94/02602, WO 96/34096 and WO 96/33735. Antibodies to be employed in accordance with the invention or their corresponding immunoglobulin chain(s) can be further modified using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s).

known in the art either alone or in combination. Methods for introducing such modifications in the DNA sequence underlying the amino acid sequence of an immunoglobulin chain are well known to the person skilled in the art; see, e.g., Sambrook (1989), loc. cit..

The term "monoclonal" or "polyclonal antibody" (see Harlow and Lane, (1988), loc. cit.) also relates to derivatives of said antibodies which retain or essentially retain their binding specificity. Whereas particularly preferred embodiments of said derivatives are specified further herein below, other preferred derivatives of such antibodies are chimeric antibodies comprising, for example, a mouse or rat variable region and a human constant region.

The term "scFv fragment" (single-chain Fv fragment) is well understood in the art and preferred due to its small size and the possibility to recombinantly produce such fragments.

The term "specifically binds" in connection with the antibody used in accordance with the present invention means that the antibody etc. does not or essentially does not cross-react with (poly)peptides of similar structures. Cross-reactivity of a panel of antibodies etc. under investigation may be tested, for example, by assessing binding of said panel of antibodies etc. under conventional conditions (see, e.g., Harlow and Lane, (1988), loc. cit.) to the (poly)peptide of interest as well as to a number of more or less (structurally and/or functionally) closely related (poly)peptides. Only those antibodies that bind to the (poly)peptide/protein of interest but do not or do not essentially bind to any of the other (poly)peptides which are preferably expressed by the same tissue as the (poly)peptide of interest, are considered specific for the (poly)peptide/protein of interest and selected for further studies in accordance with the invention.

The invention also provides a ~~method~~ of treating depression comprising the administration of (a) geldanamycin or a geldanamycin derivative that can disrupt and inhibit the association between FKBP52 and Hsp90; and/or (b) an antibody or an

~~immunotherapeutic agent that inhibits the interaction of FKBP52 and Hsp90 or an antibody that inhibits the interaction of FKBP52 and Hsp90.~~

~~ImmunoGen, Inc.~~

The Figures show:

Figure 1. Representation of linkage disequilibrium (LD) structure using D' in the FKBP51 region. The 4 SNPs of the invention are labelled with a red arrow. The quantity D' (D prime) measures the amount of linkage disequilibrium between alleles at two loci. It is defined as the difference between an observed haplotype frequency and its expected value under the assumption of no disequilibrium. This difference is then divided by its theoretical maximum. The range of D' therefore goes from 0, indicating no linkage disequilibrium to 1, indicating maximum disequilibrium. D' is defined and first published by Lewontin in 1964²⁷.

Figure 2. Association of SNPs in the FKBP51 gene region and response to antidepressant drugs at week 2. The -log p values (y axis) of the association were plotted against the physical location of the SNPs (x axis).

Figure 3. Hamilton Depression Rating Scale (HAM-D) scores over the first 5 weeks of hospitalisation according to the rs1360780 genotype. A repeated measures ANOVA showed an overall significant genotype effect: $F_{197,2} = 5.3$, $p = 0.0058$. Patients did not differ in disease severity at admission: mean HAM-D score at admission (SD) for CC = 26.2 (7.3); CT = 25.7 (8.1); TT = 26.2 (7.2). A one way ANOVA showed a non-significant genotype effect for differences in HAM-D scores at admission: $F_{277,2} = 0.15$, $p = 0.86$.

Figure 4. Effect of rs1360780 genotype on ACTH response in the Dex-CRH test at admission and discharge. A t-test showed that peak ACTH values ($T = 3.48$; $df = 95.8$; $p = 0.00075$) and area under the curve of the ACTH response ($T = 1.92$; $df = 98.1$; $p = 0.056$) were significantly lower in the TT genotype vs. the two other genotypes. The cortisol response at admission and the ACTH and cortisol responses at discharge were not significantly different between these two groups.

Figure 5. Number of previous depressive episodes and rs1360780 genotype.

Figure 6. HAM-D scores over the first 5 weeks of hospitalisation against rs3800372 genotypes. A repeated measures ANOVA showed an overall significant genotype

effect: $F_{197,2} = 4.5$, $p = 0.014$ and interaction between response and genotype: $F_{197,4.5} = 2.6$, $p = 0.03$. Patients did not differ in disease severity at admission: mean HAM-D score at admission (SD) for CC = 26.6 (7.1); TC = 25.7 (8.2); TT = 26.1 (7.4). A one-way ANOVA showed a non-significant genotype effect for differences in HAM-D scores at admission: $F_{280,2} = 0.18$, $p = 0.83$.

Figure 7. Number of previous depressive episodes and rs3800372 genotype. A one way ANOVA showed a significant genotype effect: $F_{258,2} = 4.3$; $p = 0.014$.

Figure 8. Western blot of FKBP51 protein for the various genotype of the rs3800372 SNP.

Figure 9. FKBP51 protein levels for the various genotype of the rs3800372 SNP.

The Examples illustrate the invention.

Example 1

Methods

Patients:

256 patients admitted to our psychiatric hospital for treatment of a depressive disorder presenting with a unipolar depressive episode (86.6%), bipolar disorder (12.0%) or dysthymia (1.2%) as their primary psychiatric diagnoses were recruited for the study. Patients were included in the study within 1-3 days of admission to our hospital and the diagnosis was ascertained by trained psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria. Depressive disorders due to a medical or neurological condition were exclusion criteria. Ethnicity was recorded using a self-report sheet for perceived nationality, mother language and ethnicity of the subject itself and all 4 grandparents. All included patients were Caucasian and 92 % of German origin. The study has been approved by the local ethics committee. Written informed consent was obtained from all subjects. Severity of psychopathology at admission was assessed using the 21 items Hamilton Depression Rating Scale (HAM-D) by trained raters, including residents in psychiatry and psychologists. Ratings were performed within 3 days of admission and then in weekly intervals until discharge.

DNA preparation:

On enrollment in the study, 40 ml of EDTA blood were drawn from each patient and DNA was extracted from fresh blood using the Puregene® whole blood DNA-extraction kit (Gentra Systems Inc; MN).

Genotyping:

86 SNPs in the FKBP51 locus were selected from the public SNP database dbSNP (<http://www.ncbi.nlm.nih.gov:80/>). Prior to genotyping, the relevant regions were amplified by PCR. Table 6 shows the PCR primers used. The four SNPs showing the most significant correlation with antidepressant response are shown in bold. Genotyping was performed on a MALDI-TOF mass-spectrometer (MassArray®)

system) employing the Spectrodesigner software (SequenomTM; CA) for primer selection and multiplexing and the homogeneous mass-extension (hMe) process for producing primer extension products. Table 7 shows the primers used for the primer extension assays. Again, The four SNPs showing the most significant correlation with antidepressant response are shown in bold.

Table 6

| SNP-ID | sense | antisense |
|-----------|---------------------------------|---------------------------------|
| rs1334894 | ACGTTGGATGCTTCATCCCAGCATTTC | ACGTTGGATGCCCTATGGCCTCAAAAG |
| rs1360780 | ACGTTGGATGAAGAGATCCAGGCACAGAAG | ACGTTGGATGTGCCAGCAGTAGCAAGTAAG |
| rs15258 | ACGTTGGATGGTCAGTATGGCAAATGAGTG | ACGTTGGATGTTTCAGCCC GG GTATAAGC |
| rs1546428 | ACGTTGGATGAAACCGAACGCAGAGTCACTC | ACGTTGGATGGCTGAAAATCCGGAAAAAG |
| rs1802039 | ACGTTGGATGGAGGTGAGCAGAAAAAGGC | ACGTTGGATGTCAGGTAAATTCCGCTCCAG |
| rs1803817 | ACGTTGGATGTGGAGAGGGCTATGTTCTG | ACGTTGGATGCACAGAGATGAAGGAGGAGC |
| rs1903370 | ACGTTGGATGCATTGTGTATCCTTCCAGGC | ACGTTGGATGAGGGACTACAAATCAGTCTG |
| rs1981656 | ACGTTGGATGTACTCACTTCTCCCCCTTC | ACGTTGGATGTAGTGGACAAAGACTCGGTC |
| rs2118727 | ACGTTGGATGAGCTCCAAAGTATGCTACCG | ACGTTGGATGTCTAGCCCACAGTTGTGATG |
| rs2290893 | ACGTTGGATGAGCCTCTCCAAGATAGGTC | ACGTTGGATGGCTCTCAGCGATTCGTAG |
| rs258813 | ACGTTGGATGTTGATCATGGGAAGACATGG | ACGTTGGATGTAGGATGCGCCTTTCTCC |
| rs2740204 | ACGTTGGATGTGTGTTCTCTGGGTGTC | ACGTTGGATGAACTGCTAAGAACGTGTCCG |
| rs2958153 | ACGTTGGATGAAGCCTAGGGTGAAGTTAC | ACGTTGGATGCCCTACTTTACCCCTTGGC |
| rs2958154 | ACGTTGGATGCCAGCATTCACTACATGATAG | ACGTTGGATGGCATGTTCAGAGTCCAGAG |
| rs3021522 | ACGTTGGATGACCCAGGAGAGAAACAAAG | ACGTTGGATGCAGGGCTTCCATCTAAAG |
| rs3176921 | ACGTTGGATGTATGAGCCTGCAGAACAG | ACGTTGGATGTGGGAGTAGCTCTTGTCA |
| rs3204090 | ACGTTGGATGTCCCCAACTGGCTATGAAAC | ACGTTGGATGAGGAAACCTCAGTAGTCCTC |
| rs33388 | ACGTTGGATGTCTGCCCTGAATGAATGGGTG | ACGTTGGATGTGGGTGAAAGTCATGGATGG |
| rs38391 | ACGTTGGATGCTACCTACGGGGTCTCAGAAG | ACGTTGGATGGCTGAGCTTGTGGTACGTTG |

| | | |
|-----------|---------------------------------|-----------------------------------|
| rs6188 | ACGTTGGATGTAAACTGTGTAGCGCAGACC | ACGTTGGATGTGTAGTGGCCTGCTGAATTG |
| rs6191 | ACGTTGGATGTTCCATCTGGCTGGTCAC | ACGTTGGATGCCTCTGACACTAAAACAG |
| rs6192 | ACGTTGGATGCCAAGCAGCGAAGACTTTG | ACGTTGGATGACTGCTTGGACAGATCTGG |
| rs6195 | ACGTTGGATGCATTCCACCAATTCCCGTTG | ACGTTGGATGTCCCCAGAGAAGTCAAGTTG |
| rs6196 | ACGTTGGATGGGCAGTCACTTTGATGAAAC | ACGTTGGATGCCGAGATGTTAGCTGAAATC |
| rs6597 | ACGTTGGATGCTGGCAAGCAGGAATGTGG | ACGTTGGATGAGATGGACCTGGCCAGATGTC |
| rs706118 | ACGTTGGATGAATGTCTGGCCATAGGAAC | ACGTTGGATGTTCCCTGTCACAATGAGCCC |
| rs706120 | ACGTTGGATGAGACTGGAACTCAGGACTTG | ACGTTGGATGTAGGTCTAGCAGCTTCTGC |
| rs734369 | ACGTTGGATGATAAGGCTGCAAGACTGCAG | ACGTTGGATGATGTTGGCGTATATCCTGCG |
| rs737054 | ACGTTGGATGACAAGGTGACCGAGAACATG | ACGTTGGATGGGTATATTGGTCAGGTGCC |
| rs755658 | ACGTTGGATGACTAGGATTTACCACAGCCC | ACGTTGGATGGGTGAGGGTTGGAGTATTG |
| rs2103681 | ACGTTGGATGCTTGAGCTGACATGAGCATTG | ACGTTGGATGAAACAGCTGACCCACAGAACATC |
| rs1883636 | ACGTTGGATGAGTCCTGAGGGTTCACTCAG | ACGTTGGATGTCTTACTGGGCCAAACAAG |
| rs1540910 | ACGTTGGATGTGCTCCAAAGTCCCTATTCC | ACGTTGGATGTTGCATGTCAGGAGATCTGG |
| rs4713878 | ACGTTGGATGCTAAACACTGGCTGTGTGAC | ACGTTGGATGTTCATCCTCACAGCACACTC |
| rs1883637 | ACGTTGGATGAGAAGCTGGGAGATTCTC | ACGTTGGATGGGCCCTGAATCAGTCTTAAG |
| rs992105 | ACGTTGGATGGCATGGCCTTAACTTGTG | ACGTTGGATGGAACGTACTCTGGTAAGCAC |
| rs1051952 | ACGTTGGATGAAACATCTGGAGTTGGAGCCG | ACGTTGGATGGGGAGAGGGGAGGTTAAA |
| rs2273000 | ACGTTGGATGAGAATCCTCTGTCCCTCCTC | ACGTTGGATGAATTCTCCCCACGATGGTC |
| rs4713897 | ACGTTGGATGGCCCTGAGTATACTTTCTGG | ACGTTGGATGCACTGGCATTGCCATT |
| rs734369 | ACGTTGGATGATAAGGCTGCAAGACTGCAG | ACGTTGGATGATGTTGGCGTATATCCTGCG |
| rs747411 | ACGTTGGATGGACGTGACACCACACTTGAC | ACGTTGGATGAGGCAGGAGGATCTCTTGAG |
| rs1320991 | ACGTTGGATGGTGTGCGTATGCATACTGTG | ACGTTGGATGTGCCTGCACTGAAAACATGC |
| rs737054 | ACGTTGGATGACAAGGTGACCGAGAACATG | ACGTTGGATGGGTATATTGGTCAGGTGCC |
| rs3777747 | ACGTTGGATGCCACTCTTACATTCCCTCCTC | ACGTTGGATGTCCCTCTCCAAATCTCACTG |
| rs4401662 | ACGTTGGATGAATTGCTTGAACCCAGGAGG | ACGTTGGATGAGTCTTGCCTGTCATCCAG |
| rs4713908 | ACGTTGGATGATTCCGTTGTGTGTATGC | ACGTTGGATGTCAGACATCTGTCATTCTTC |
| rs755658 | ACGTTGGATGACTAGGATTTACCACAGCCC | ACGTTGGATGGGTGAGGGTTGGAGTATTG |
| rs4713899 | ACGTTGGATGAGTGGAGCTAGGAGCTAG | ACGTTGGATGACGGAAAGACTGCTGATTGC |
| rs1360780 | ACGTTGGATGAAGAGATCCAGGCACAGAAC | ACGTTGGATGTGCCAGCAGTAGCAAGTAAG |
| rs4713907 | ACGTTGGATGTCCCTGACTTTGTGATCCACC | ACGTTGGATGATACCATACTCTAGGCTGGG |
| rs3800372 | ACGTTGGATGAAACACCAAGAGAAGCAGCTC | ACGTTGGATGCTATCCACCTCCTCCATAAG |

| | | |
|-----------|---------------------------------|----------------------------------|
| rs2092427 | ACGTTGGATGACCTGCAGTACTTTGGCAG | ACGTTGGATGCAGACACTTCTAAGTGCTG |
| rs4713905 | ACGTTGGATGTTCAATACCTCACCTGTCTC | ACGTTGGATGGTGTATTCTGCTTGTATTGGG |
| rs4520009 | ACGTTGGATGACGAACAGGAAACTGAAAGC | ACGTTGGATGGAGCATGGTTTCAGTAAAG |
| rs4713906 | ACGTTGGATGAAGTATTGTGGCTGGAGGC | ACGTTGGATGATCTCCTGACCTTGTGATCC |
| rs4713916 | ACGTTGGATGTATCTGGCAACCCCTAACCTC | ACGTTGGATGCCCTAACGAGATAGTGAGGAG |
| rs2143404 | ACGTTGGATGGGTTAGGTAGAGCTCAGTTC | ACGTTGGATGGTAGAGAACCTGGTAAGAAG |
| rs4713902 | ACGTTGGATGGGAGCCAAAACATGAAGAGC | ACGTTGGATGTAGGCAACCTGTATAAGCTG |
| rs1334894 | ACGTTGGATGCTTGTCACTCCAGCATCTC | ACGTTGGATGCCCTATTGGCCTCAAAAAG |
| rs1475774 | ACGTTGGATGCAAGTGAAAAACTCCACACC | ACGTTGGATGCCATAAGTCTTGTCCACAAG |
| rs2817035 | ACGTTGGATGCCTCTTTCTCCTAGGATCC | ACGTTGGATGGTTGCAAACAGAGGTAGGAG |
| rs3807050 | ACGTTGGATGAGAGGGAGGGAAATAGTCAG | ACGTTGGATGTGTCTCCAAGACTGTGTG |
| rs1977655 | ACGTTGGATGCCCGTCTCTGCTAAAAATAC | ACGTTGGATGCCAAGTTCAAGCGATTCTG |
| rs3800374 | ACGTTGGATGAGACGATGGACCCATTTCAC | ACGTTGGATGTCTTCCAAGTGGTGAACC |
| rs4713912 | ACGTTGGATGAGGTTCAAGCGATTCTCCTG | ACGTTGGATGCCAAAATTAGCCGGCTTGG |
| rs2817047 | ACGTTGGATGTCCTGGCTCAAGTGATTCTC | ACGTTGGATGAATTAGCCAGGCATGATGGC |
| rs4713913 | ACGTTGGATGGAATTAACTAGGAGTGCTG | ACGTTGGATGAGCGAGACTCCGTCTCAAAA |
| rs4713921 | ACGTTGGATGAAGCCCTGTGGTTTATGCC | ACGTTGGATGTGGAACAATTCTGTCCCCAG |
| rs2817041 | ACGTTGGATGGTACACACAGCGAGTGATAC | ACGTTGGATGCTCCTCAACTCTTGGAGTG |
| rs2766543 | ACGTTGGATGTCGTGGTGGCTTTCTC | ACGTTGGATGAAGCAGAGCTGCCAATAAG |
| rs5020575 | ACGTTGGATGTGATCTGGCTCACTGCAAC | ACGTTGGATGAAATTAGCCAAGCGTGGTGG |
| rs1591365 | ACGTTGGATGGTGGCAAATAGGAGTCTCC | ACGTTGGATGTTGGCAGGTGTTTCTGAG |
| rs2296662 | ACGTTGGATGAATTGGCCTATGACCAGCAC | ACGTTGGATGAAGAGGGAGGAGAAACCAAGAG |
| rs2817010 | ACGTTGGATGTGGTGTGTATGAGAACGAGC | ACGTTGGATGTAAGTCTGTGCAGACGGTGG |
| rs873941 | ACGTTGGATGGGTTGATGCTTTGCAACTC | ACGTTGGATGGCTATGATACCTGGCTGATC |
| rs3800373 | ACGTTGGATGAAACCCCTAGTGTAGAAGAG | ACGTTGGATGTTACACTCCTCTATCATGC |
| rs4713903 | ACGTTGGATGGAGTCTAACAAAAACATCC | ACGTTGGATGAAGTACTGGGATTACAGGTG |
| rs2766534 | ACGTTGGATGTCGAAGGGACTTATTCCCTCC | ACGTTGGATGCCCTGGAGGAGGAGCTCAG. |

| SNP-ID | extension primer |
|-----------|----------------------------|
| rs1334894 | TTGATGACTTAGTCCTGTC |
| rs1360780 | GGCTTCACATAAGCAAAGTTA |
| rs15258 | TTTAATACACTATTGGATTTTT |
| rs1546428 | AATATGCCTCCTGGCGTT |
| rs1802039 | AGCAGAAAAAGGCTGTGCTGCC |
| rs1803817 | CTATGCTTCTGTCTCCAC |
| rs1903370 | TCCTTCCAGGCTTTCTTTAG |
| rs1981656 | CAAGAGAGAGGGCACAGGT |
| rs2118727 | AAAGTATGCTACCGGAAACAC |
| rs2290893 | GTAAATTATGAGACAAACTTT |
| rs258813 | CTAACTACAGTGATTTGTC |
| rs2740204 | TGGGTGTCTGTGGCTCT |
| rs2958153 | GTTACCGAAAGAGGGCGAGTA |
| rs2958154 | AGCTTGTCAATTCTCACCTT |
| rs3021522 | GAGTCACGTACAGGGTG |
| rs3176921 | AGCCTGCAGAACAGCAAGGCCAATAA |
| rs3204090 | GTTATTGACGCATTCATCTCTGA |
| rs33388 | ATGCTTCTCTAGGTGTGTGA |
| rs33391 | CCTCTGAAAATCCTGGTAA |
| rs5195 | GCTGCCAGGAGGAGAACTACCTGC |
| rs6156 | GGAAGACAACCTCCAGAG |
| rs6157 | CAGAGAGACGTCTCCGG |
| rs6158 | GCGCTTCGCAGGTGAGC |
| rs6159 | CTCCTCGCTCCTCGCCGG |
| rs6188 | TTACAGTTCATTCTATGTATTT |
| rs6191 | CTGTAGGTGAATGTGTTTTT |
| rs6192 | GCGAAGACTTTGGTTGAT |
| rs6195 | TTCCCGTTGGTTCCGAAA |
| rs6196 | ACAGAAGTTTTGATATTCC |
| rs6597 | TGGGGAAGTGTGGATGTTAGC |

| | |
|-----------|--------------------------|
| rs706118 | TGGGCCATAGGAACGTGATCT |
| rs706120 | TCAGGACTTGCACAAAGAGAA |
| rs734369 | AAGACTGCAGATCTCCATGTGCCA |
| rs737054 | GACGCCAGGCACAGCC |
| rs755658 | GC CGTACATCTCACTG |
| rs2103681 | ATCTATTCTGTAAAACTCAG |
| rs1883636 | CCCACAGTTGCCTTCC |
| rs1540910 | CTTCCCTGGAAACCCCAAG |
| rs4713878 | GACAAGTTACTTAACCTCTTGAG |
| rs1883637 | CCACTAGAGCCCCATAATTCCTC |
| rs992105 | TCACCTTGTATTTCTAAAGAT |
| rs1051952 | TCCGGGAGCAGTAGTCA |
| rs2273000 | GGGTGGAGGCATATATTGGTCT |
| rs4713897 | TTCTGGAACATAATGTGAGC |
| rs734369 | GCAGATCTCCATGTGCCA |
| rs747411 | CTATGCTGCCTGGCTGGTCTC |
| rs1320991 | GCGTATGCATACTGTGTATA |
| rs737054 | GACGCCAGGCACAGCC |
| rs3777747 | ATTCCTCTCCTTCAGC |
| rs4401662 | GAGCTGCGATAGCATCACT |
| rs4713908 | TGTTTCTTACTCATTTAACCTTA |
| rs755658 | GCGCGTACATCTCACTG |
| rs4713899 | AGGCTCATCTGCATCTGTAC |
| rs1360780 | AGGCTTCACATAAGCAAAGTTA |
| rs4713907 | CTCTAGAATCCGTAGAATC |
| rs3300372 | GAAGCAGCTCCCTTCTAGA |
| rs2088137 | ACCGCTTCTCTACGACTCGGAA |

| | |
|-----------|---------------------------|
| rs4713902 | CATGAAGAGCTAATTCTTTATCA |
| rs1334894 | GGAAGTTGATGACTTAGTCCTGTC |
| rs1475774 | CTTGTCTTAATGATTCAAG |
| rs2817035 | GGCTCCCTACTCCACCACTAC |
| rs3807050 | CCAGTAAAGACTTGCTGA |
| rs1977655 | TCTGCTAAAAATAACAAAAATAGCC |
| rs3800374 | CCCATTACAGTTATGGGCTC |
| rs4713912 | GCCACCCGAGAAGCTGGGATTA |
| rs2817047 | CCCCCCAAGTAGCTGGGACTACA |
| rs4713913 | GTGTTTTGTTGTTGTTGTTGTT |
| rs4713921 | CAGTTGAAAGAGCCTCAC |
| rs2817041 | GTGCAGGATCATGCTCTGGC |
| rs2766543 | CTTTCTCCCTGCTACGT |
| rs5020575 | AGTGATTCTCGTGCCTCA |
| rs1591365 | TGTCAGTTGTTTCCCTTGAA |
| rs2296662 | CTGGGCTCGCTTCCCTCCC |
| rs2817010 | AGAACGAGCTATGTTGAGG |
| rs873941 | TTTGCAACTCACTTTTTAAAA |
| rs3800373 | AAGAGCAACTATTTATTTGTCAAC |
| rs4713903 | CCAAACAACTAAATTGGGAAA |
| rs2766534 | CCGCCCTACACTTTCAC |
| rs2766554 | CTTTTGCCCTCACATTCTT |
| rs2817054 | AGCAGCGGCTCAGGCAG |
| rs2766597 | AGAAGATCCTGATCCTCC |

Neuroendocrine assessment using the combined dexamethasone suppression/CRH stimulation (Dex-CRH) test:

The Dex-CRH test was performed as described in detail in Heuser et al., 1994¹⁸. Patients were administered the test within the first ten days of admission (n= 225) and the last ten days of discharge (n = 150). Briefly, patients were pre-treated with 1.5 mg of dexamethasone per os at 23:00. The following day a venous catheter was

placed at 14:30 and blood was drawn at 15:00, 15:30, 15:45, 16:00 and 16:15 into tubes containing EDTA and trasylol (Bayer Inc., Germany). At 15:02 100 μ g of human CRH (Ferring Inc., Kiel, Germany) was administered intravenously. For the area under the curve (AUC) of the cortisol and ACTH response, the area under the concentration-time course curve corrected for the baseline value at 15:00 was computed using a trapezoidal integration for the test at admission as well as at discharge. Hormone assays for the Dex-CRH test were identical to those described in detail in Zobel et al., 2001¹⁷.

Quantification of FKBP51 protein levels in lymphocytes:

T cells were extracted from the whole blood of healthy controls using magnetic beads with antibodies against CD2 (Dynal Inc.). Cells were then lysed in a protein lysis buffer. Protein levels of FKBP51 were assessed using Western-blot analysis.

For protein extraction cells were solubilized in 1ml lysis buffer (20 mM Tris/HCl pH 7.5; 130 mM NaCl; 20 mM Na₂MoO₄; 1 mM EDTA; 10% glycerol; 0.5% Triton 100; 1:100 protease inhibitor cocktail P2714 from Sigma). The extract was incubated for 1 h on ice, centrifuged for 4 min at 13000 rpm and protein concentration was determined.

For immunoblot detection 10 μ g of cell lysates' total protein were separated by SDS-PAGE under denaturing conditions. The proteins were transferred to polyvenylidene difluoride membrane (Schleicher & Schüll GmbH, Germany). Nonspecific binding to membrane was blocked by 5% nonfat milk in Tris-buffered saline/Tween buffer. FKBP51 was detected by a monoclonal anti-FKBP51 antibody (Stress Gen Biotech) followed by horseradish peroxidase-conjugated rabbit anti-mouse antibody (Sigma). Signals were visualized by ECL solution (Amersham Pharmacia Biotech) and monitored in an imaging-system (Kodak-Imaging Station 440). Light emission was normalized by the intensity of ~~cocounting~~ FKBP5 standard that was loaded onto each gel to ensure accurate comparison of probes loaded on different gels.

Statistical analyses:

All data are expressed as mean \pm SEM. Statistical significance was determined by unpaired Student's t-test.

** p < 0.01, * p < 0.05.

Example 2

Association study of polymorphisms in FKBP51 and response to antidepressant drugs

4 SNPs in FKBP51 (see table 1) were genotyped in 327 patients with major depression. 103 of them showed an improvement of over 25% in disease severity as measured by the Hamilton Depression Rating Scale (HAM-D) after two weeks of treatment with an antidepressant (response), while 156 (non-response) showed less than 25% improvement. The patient population used for the studies comprises of individuals that were treated with various antidepressant drugs including, Amitriptylin, Amitriptylinoxid, Clomipramin, Doxepin, Imipramin, Nortriptylin, Trimipramin, Citalopram, Fluoxetin, Fluvoxamin, Paroxetin, Sertralin, Tianeptin, Mirtazapin, Venlafaxin, Reboxetin, Moclobemid, Tranylcypromin, Bupropion, Buspiron, Dibenzepin, Nefazodon, Opipramol, Sibutramin, and Trazodon. Most patients received only one of these antidepressants as monotherapy regimen, but some individuals received combination therapy (i.e. more than one antidepressant).

We could show a significant association of 4 SNPs in FKBP51 with response after 2 weeks of treatment.

| SNP | Non-responders (n = 156) | Responders (n = 103) | p-value |
|-----------|-----------------------------|------------------------------|------------------------|
| rs4713916 | AA:1.0%, AG:41.0%, GG:58.0% | AA:16.1%, AG:33.6%, GG:50.8% | 5.5 x 10 ⁻⁵ |
| rs3800372 | CC:1.0%, TC:36.9%, TT:62.1% | CC:17.9%, TC:26.3%, TT:55.8% | 5.5 x 10 ⁻⁶ |
| rs1360780 | TT:1.0%, CT:40.8%, CC:58.2% | TT:14.7%, CT:35.9%, CC:49.3% | 1.2 x 10 ⁻⁴ |
| rs3800373 | CC:0.0%, CA:37.9%, AA:62.1% | CC:13.5%, CA:33.8%, AA:52.7% | 2.8 x 10 ⁻⁵ |

Table 8: Association of SNPs in FKBP51 with response at 2 weeks.

This effect, however, was not limited to response at 2 weeks, but could be observed during the whole in-patient treatment course. This is illustrated with rs1360780 in Figure 3 and with rs3800372 in Figure 6.

All 4 SNPs genotyped in *FKBP51* are in strong linkage disequilibrium (see figure 1). This implies that the causal variant could lie anywhere within the linkage disequilibrium block defined by these SNPs.

Example 3

Association of rs1360780 genotype with HPA-axis activity

To investigate changes of HPA-axis activity from admission to discharge, we used the Dex-CRH test, which sensitively identifies GR-signaling impairment¹⁸. By comparing the ACTH and cortisol responses in this test of patients with CC/CT or TT genotypes of rs1360780, we observed that at admission T homozygotes displayed a significantly lower ACTH response following CRH stimulation than patients with the CC or CT genotypes (figure 4). An elevated ACTH response in this test indicates an impaired negative feedback through GR. Our finding thus suggests that, even though T homozygotes are as severely depressed as patients with the two other rs1360780 genotypes, their GR sensitivity is not as much impaired, allowing a faster restoration of normal HPA-axis function by antidepressants and thus an accelerated clinical response.

Example 4

Association of rs1360780 genotype and *FKBP51* protein expression in lymphocytes

Polymorphisms in *FKBP51* could influence GR sensitivity by several means. Polymorphisms in regulatory regions could lead to an altered expression level of *FKBP51*, thereby the stoichiometric proportions of FKBP51 and GR could change. In addition, variants in the coding region could affect the function of the protein.

could thus lead to a maintained GR sensitivity despite high circulating cortisol levels, resembling somewhat the neuroendocrine situation observed in T homozygotes. In order to investigate whether the genotype of rs1360780 was associated with different levels of FKBP51 protein, we quantified this protein in lymphocytes (T-cells) of healthy probands. Semi-quantitative analysis of Western blot results (see Figure 8) revealed that probands homozygous for the T allele of rs1360780 showed the lowest FKBP51 protein levels in lymphocytes (see Figure 9). Lower levels of FKBP51 thus could be associated with an enhanced GR sensitivity that would prevent long-lasting dysregulations of the HPA-axis (see Figure 4) and in consequence a faster response to antidepressant drugs (see Figure 3).

References

1. Holsboer, F. The Corticosteroid Receptor Hypothesis of Depression. *Neuropsychopharmacology* **23**, 477-501 (2000).
2. Nemeroff, C. B. & Owens, M. J. Treatment of mood disorders. *Nat Neurosci* **5**, 1068-70. (2002).
3. Holsboer, F. & Barden, N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. *Endocrine Reviews* **17**, 187-205 (1996).
4. Nemeroff, C. B. The role of corticotropin-releasing factor in the pathogenesis of major depression. *Pharmacopsychiatry* **21**, 76-82. (1988).
5. Nemeroff, C. B. et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. *Science* **226**, 1342-4. (1984).
6. Nemeroff, C. B., Owens, M. J., Bissette, G., Andorn, A. C. & Stanley, M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. *Arch Gen Psychiatry* **45**, 577-9. (1988).
7. Purba, J. S., Hoogendoijk, W. J., Hofman, M. A. & Swaab, D. F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. *Archives of General Psychiatry* **53**, 137-43 (1996).
8. Timpl, P. et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. *Nature Genetics* **19**, 162-6 (1998).
9. Pariante, C. M. & Miller, A. H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. *Biol Psychiatry* **49**, 391-404. (2001).
10. Reul, J. M., Stec, I., Soder, M. & Holsboer, F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. *Endocrinology* **122**, 812-20. (1983).

- depends on innate emotionality in rats. *European Journal of Neuroscience* 13, 1-10 (2001).
13. Nickel, T. et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. *J Clin Psychopharmacol* 23, 155-68. (2003).
 14. Barden, N., Stec, I. S., Montkowski, A., Holsboer, F. & Reul, J. M. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. *Neuroendocrinology* 66, 212-20 (1997).
 15. Pratt, W. B. & Toft, D. O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr Rev* 18, 306-60. (1997).
 16. Cheung, J. & Smith, D. F. Molecular chaperone interactions with steroid receptors: an update. *Mol Endocrinol* 14, 939-46. (2000).
 17. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001): Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. *J Psychiatr Res* 35:83-94.
 18. Heuser, I., Yassouridis, A. & Holsboer, F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *Journal of Psychiatric Research* 28, 341-56 (1994).
 19. Schiene-Fischer, C. & Yu, C. Receptor accessory folding helper enzymes: the functional role of peptidyl prolyl cis/trans isomerases. *FEBS Lett* 495, 1-6. (2001).
 20. Davies, T. H., Ning, Y. M. & Sanchez, E. R. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. *J Biol Chem* 277, 4597-600. (2002).
 21. Denny, W. B., Valentine, D. L., Reynolds, P. D., Smith, D. F. & Scammell, J. G. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. *Endocrinology* 141, 4107-13. (2000).
 22. Reynolds, P. D. et al. Glucocorticoid-resistant B-lymphoblast cell line derived from the Bolivian squirrel monkey (*Saimiri boliviensis boliviensis*). *Lab Anim Sci* 48, 364-70. (1998).
 23. Scammell, J. G., Denny, W. B., Valentine, D. L. & Smith, D. F. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. *Gen Comp Endocrinol*

- 124, 152-65. (2001).
24. Vermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C. & Jansen, M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. *J Clin Endocrinol Metab* **88**, 277-84. (2003).
25. Zhang, K., and Jin L., HaploBlockFinder: haplotype block analyses. *Bioinformatics* **19**, 1300-1301 (2003)
26. Reynolds, P. D., Ruan, Y., Smith, D. F., and Scammel, J. G. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. *J Clin Endocrinol Metab* **84**, 663-669. (1999).
27. Lewontin, R. C. The interaction of selection and linkage. I. General considerations; heterotic models. *Genetics* **49**, 49-67 (1964).

EPO - Munich
33
25 Nov. 2003

Claims

1. A method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said individual for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample.
2. The method of claim 1, wherein said individual is a patient suffering from depression and said classifying consists of or comprises predicting the response to therapy.
3. The method of claim 1, wherein said classifying consists of or comprises selecting said individual for a clinical trial.
4. The method of claim 1 or 2, wherein said individual is a patient suffering from depression and said classifying consists of or comprises predicting the predisposition for an elevated number of episodes of depression.
5. The method of claim 3, further comprising the steps:
 - (a) identifying a compound modulating the activity of FKBP51; and optionally
 - (b) optimizing the pharmacological properties of the compound identified in (a); and
 - (c) performing said clinical trials;
wherein said clinical trials are clinical trials of the compound identified in (a) or optimized in (b).
6. The method according to claim 5, wherein the compound modulating the activity of FKBP51 is an activator of FKBP51.
7. The method according to claim 5 or 6, wherein the compound modulating the activity of FKBP51 increases the expression of FKBP51.

8. The method of any one of claims 1 to 7, wherein the nucleic acid is gDNA.
9. The method of any one of claims 1 to 8, wherein the haplotype block comprises at least one SNP selected from the group consisting of rs4713916, rs3800372, rs1360780 and rs3800373.
10. The method of any one of claims 1 to 9, wherein the polymorphism is a SNP in a non-coding region of said haplotype block.
11. The method of any one of claims 1 to 10, wherein the polymorphism is at least one SNP selected from the group consisting of rs4713916, rs3800372, rs1360780 and rs3800373.
12. The method of any one of claims 1 to 11, wherein analyzing the nucleic acid comprises:
 - (a) a primer extension assay;
 - (b) a differential hybridization assay; and/or
 - (c) an assay which detects allele-specific enzyme cleavage.
13. The method of any one of claims 1 to 12 further comprising, prior to analyzing, amplification of at least a portion of said haplotype block.
14. The method of claim 13, wherein said amplification is effected by or said amplification is the polymerase chain reaction (PCR).
15. The method of claim 13 or 14, wherein said amplification reaction uses primers which hybridize specifically with a portion of said haplotype block.
16. The method of claim 15, wherein the primers to be used for said amplification reaction have the sequences set forth in SEQ ID NO:1 and 2, 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, 19 and 21, 20 and 22, 21 and 23, 22 and 24, 23 and 25, 24 and 26, 25 and 27, 26 and 28, 27 and 29, 28 and 30, 29 and 31, 30 and 32, 31 and 33, 32 and 34, 33 and 35, 34 and 36, 35 and 37, 36 and 38, 37 and 39, 38 and 40, 39 and 41, 40 and 42, 41 and 43, 42 and 44, 43 and 45, 44 and 46, 45 and 47, 46 and 48, 47 and 49, 48 and 50, 49 and 51, 50 and 52, 51 and 53, 52 and 54, 53 and 55, 54 and 56, 55 and 57, 56 and 58, 57 and 59, 58 and 60, 59 and 61, 60 and 62, 61 and 63, 62 and 64, 63 and 65, 64 and 66, 65 and 67, 66 and 68, 67 and 69, 68 and 70, 69 and 71, 70 and 72, 71 and 73, 72 and 74, 73 and 75, 74 and 76, 75 and 77, 76 and 78, 77 and 79, 78 and 80, 79 and 81, 80 and 82, 81 and 83, 82 and 84, 83 and 85, 84 and 86, 85 and 87, 86 and 88, 87 and 89, 88 and 90, 89 and 91, 90 and 92, 91 and 93, 92 and 94, 93 and 95, 94 and 96, 95 and 97, 96 and 98, 97 and 99, 98 and 100, 99 and 101, 100 and 102, 101 and 103, 102 and 104, 103 and 105, 104 and 106, 105 and 107, 106 and 108, 107 and 109, 108 and 110, 109 and 111, 110 and 112, 111 and 113, 112 and 114, 113 and 115, 114 and 116, 115 and 117, 116 and 118, 117 and 119, 118 and 120, 119 and 121, 120 and 122, 121 and 123, 122 and 124, 123 and 125, 124 and 126, 125 and 127, 126 and 128, 127 and 129, 128 and 130, 129 and 131, 130 and 132, 131 and 133, 132 and 134, 133 and 135, 134 and 136, 135 and 137, 136 and 138, 137 and 139, 138 and 140, 139 and 141, 140 and 142, 141 and 143, 142 and 144, 143 and 145, 144 and 146, 145 and 147, 146 and 148, 147 and 149, 148 and 150, 149 and 151, 150 and 152, 151 and 153, 152 and 154, 153 and 155, 154 and 156, 155 and 157, 156 and 158, 157 and 159, 158 and 160, 159 and 161, 160 and 162, 161 and 163, 162 and 164, 163 and 165, 164 and 166, 165 and 167, 166 and 168, 167 and 169, 168 and 170, 169 and 171, 170 and 172, 171 and 173, 172 and 174, 173 and 175, 174 and 176, 175 and 177, 176 and 178, 177 and 179, 178 and 180, 179 and 181, 180 and 182, 181 and 183, 182 and 184, 183 and 185, 184 and 186, 185 and 187, 186 and 188, 187 and 189, 188 and 190, 189 and 191, 190 and 192, 191 and 193, 192 and 194, 193 and 195, 194 and 196, 195 and 197, 196 and 198, 197 and 199, 198 and 200, 199 and 201, 200 and 202, 201 and 203, 202 and 204, 203 and 205, 204 and 206, 205 and 207, 206 and 208, 207 and 209, 208 and 210, 209 and 211, 210 and 212, 211 and 213, 212 and 214, 213 and 215, 214 and 216, 215 and 217, 216 and 218, 217 and 219, 218 and 220, 219 and 221, 220 and 222, 221 and 223, 222 and 224, 223 and 225, 224 and 226, 225 and 227, 226 and 228, 227 and 229, 228 and 230, 229 and 231, 230 and 232, 231 and 233, 232 and 234, 233 and 235, 234 and 236, 235 and 237, 236 and 238, 237 and 239, 238 and 240, 239 and 241, 240 and 242, 241 and 243, 242 and 244, 243 and 245, 244 and 246, 245 and 247, 246 and 248, 247 and 249, 248 and 250, 249 and 251, 250 and 252, 251 and 253, 252 and 254, 253 and 255, 254 and 256, 255 and 257, 256 and 258, 257 and 259, 258 and 260, 259 and 261, 260 and 262, 261 and 263, 262 and 264, 263 and 265, 264 and 266, 265 and 267, 266 and 268, 267 and 269, 268 and 270, 269 and 271, 270 and 272, 271 and 273, 272 and 274, 273 and 275, 274 and 276, 275 and 277, 276 and 278, 277 and 279, 278 and 280, 279 and 281, 280 and 282, 281 and 283, 282 and 284, 283 and 285, 284 and 286, 285 and 287, 286 and 288, 287 and 289, 288 and 290, 289 and 291, 290 and 292, 291 and 293, 292 and 294, 293 and 295, 294 and 296, 295 and 297, 296 and 298, 297 and 299, 298 and 300, 299 and 301, 300 and 302, 301 and 303, 302 and 304, 303 and 305, 304 and 306, 305 and 307, 306 and 308, 307 and 309, 308 and 310, 309 and 311, 310 and 312, 311 and 313, 312 and 314, 313 and 315, 314 and 316, 315 and 317, 316 and 318, 317 and 319, 318 and 320, 319 and 321, 320 and 322, 321 and 323, 322 and 324, 323 and 325, 324 and 326, 325 and 327, 326 and 328, 327 and 329, 328 and 330, 329 and 331, 330 and 332, 331 and 333, 332 and 334, 333 and 335, 334 and 336, 335 and 337, 336 and 338, 337 and 339, 338 and 340, 339 and 341, 340 and 342, 341 and 343, 342 and 344, 343 and 345, 344 and 346, 345 and 347, 346 and 348, 347 and 349, 348 and 350, 349 and 351, 350 and 352, 351 and 353, 352 and 354, 353 and 355, 354 and 356, 355 and 357, 356 and 358, 357 and 359, 358 and 360, 359 and 361, 360 and 362, 361 and 363, 362 and 364, 363 and 365, 364 and 366, 365 and 367, 366 and 368, 367 and 369, 368 and 370, 369 and 371, 370 and 372, 371 and 373, 372 and 374, 373 and 375, 374 and 376, 375 and 377, 376 and 378, 377 and 379, 378 and 380, 379 and 381, 380 and 382, 381 and 383, 382 and 384, 383 and 385, 384 and 386, 385 and 387, 386 and 388, 387 and 389, 388 and 390, 389 and 391, 390 and 392, 391 and 393, 392 and 394, 393 and 395, 394 and 396, 395 and 397, 396 and 398, 397 and 399, 398 and 400, 399 and 401, 400 and 402, 401 and 403, 402 and 404, 403 and 405, 404 and 406, 405 and 407, 406 and 408, 407 and 409, 408 and 410, 409 and 411, 410 and 412, 411 and 413, 412 and 414, 413 and 415, 414 and 416, 415 and 417, 416 and 418, 417 and 419, 418 and 420, 419 and 421, 420 and 422, 421 and 423, 422 and 424, 423 and 425, 424 and 426, 425 and 427, 426 and 428, 427 and 429, 428 and 430, 429 and 431, 430 and 432, 431 and 433, 432 and 434, 433 and 435, 434 and 436, 435 and 437, 436 and 438, 437 and 439, 438 and 440, 439 and 441, 440 and 442, 441 and 443, 442 and 444, 443 and 445, 444 and 446, 445 and 447, 446 and 448, 447 and 449, 448 and 450, 449 and 451, 450 and 452, 451 and 453, 452 and 454, 453 and 455, 454 and 456, 455 and 457, 456 and 458, 457 and 459, 458 and 460, 459 and 461, 460 and 462, 461 and 463, 462 and 464, 463 and 465, 464 and 466, 465 and 467, 466 and 468, 467 and 469, 468 and 470, 469 and 471, 470 and 472, 471 and 473, 472 and 474, 473 and 475, 474 and 476, 475 and 477, 476 and 478, 477 and 479, 478 and 480, 479 and 481, 480 and 482, 481 and 483, 482 and 484, 483 and 485, 484 and 486, 485 and 487, 486 and 488, 487 and 489, 488 and 490, 489 and 491, 490 and 492, 491 and 493, 492 and 494, 493 and 495, 494 and 496, 495 and 497, 496 and 498, 497 and 499, 498 and 500, 499 and 501, 500 and 502, 501 and 503, 502 and 504, 503 and 505, 504 and 506, 505 and 507, 506 and 508, 507 and 509, 508 and 510, 509 and 511, 510 and 512, 511 and 513, 512 and 514, 513 and 515, 514 and 516, 515 and 517, 516 and 518, 517 and 519, 518 and 520, 519 and 521, 520 and 522, 521 and 523, 522 and 524, 523 and 525, 524 and 526, 525 and 527, 526 and 528, 527 and 529, 528 and 530, 529 and 531, 530 and 532, 531 and 533, 532 and 534, 533 and 535, 534 and 536, 535 and 537, 536 and 538, 537 and 539, 538 and 540, 539 and 541, 540 and 542, 541 and 543, 542 and 544, 543 and 545, 544 and 546, 545 and 547, 546 and 548, 547 and 549, 548 and 550, 549 and 551, 550 and 552, 551 and 553, 552 and 554, 553 and 555, 554 and 556, 555 and 557, 556 and 558, 557 and 559, 558 and 560, 559 and 561, 560 and 562, 561 and 563, 562 and 564, 563 and 565, 564 and 566, 565 and 567, 566 and 568, 567 and 569, 568 and 570, 569 and 571, 570 and 572, 571 and 573, 572 and 574, 573 and 575, 574 and 576, 575 and 577, 576 and 578, 577 and 579, 578 and 580, 579 and 581, 580 and 582, 581 and 583, 582 and 584, 583 and 585, 584 and 586, 585 and 587, 586 and 588, 587 and 589, 588 and 590, 589 and 591, 590 and 592, 591 and 593, 592 and 594, 593 and 595, 594 and 596, 595 and 597, 596 and 598, 597 and 599, 598 and 600, 599 and 601, 600 and 602, 601 and 603, 602 and 604, 603 and 605, 604 and 606, 605 and 607, 606 and 608, 607 and 609, 608 and 610, 609 and 611, 610 and 612, 611 and 613, 612 and 614, 613 and 615, 614 and 616, 615 and 617, 616 and 618, 617 and 619, 618 and 620, 619 and 621, 620 and 622, 621 and 623, 622 and 624, 623 and 625, 624 and 626, 625 and 627, 626 and 628, 627 and 629, 628 and 630, 629 and 631, 630 and 632, 631 and 633, 632 and 634, 633 and 635, 634 and 636, 635 and 637, 636 and 638, 637 and 639, 638 and 640, 639 and 641, 640 and 642, 641 and 643, 642 and 644, 643 and 645, 644 and 646, 645 and 647, 646 and 648, 647 and 649, 648 and 650, 649 and 651, 650 and 652, 651 and 653, 652 and 654, 653 and 655, 654 and 656, 655 and 657, 656 and 658, 657 and 659, 658 and 660, 659 and 661, 660 and 662, 661 and 663, 662 and 664, 663 and 665, 664 and 666, 665 and 667, 666 and 668, 667 and 669, 668 and 670, 669 and 671, 670 and 672, 671 and 673, 672 and 674, 673 and 675, 674 and 676, 675 and 677, 676 and 678, 677 and 679, 678 and 680, 679 and 681, 680 and 682, 681 and 683, 682 and 684, 683 and 685, 684 and 686, 685 and 687, 686 and 688, 687 and 689, 688 and 690, 689 and 691, 690 and 692, 691 and 693, 692 and 694, 693 and 695, 694 and 696, 695 and 697, 696 and 698, 697 and 699, 698 and 700, 699 and 701, 700 and 702, 701 and 703, 702 and 704, 703 and 705, 704 and 706, 705 and 707, 706 and 708, 707 and 709, 708 and 710, 709 and 711, 710 and 712, 711 and 713, 712 and 714, 713 and 715, 714 and 716, 715 and 717, 716 and 718, 717 and 719, 718 and 720, 719 and 721, 720 and 722, 721 and 723, 722 and 724, 723 and 725, 724 and 726, 725 and 727, 726 and 728, 727 and 729, 728 and 730, 729 and 731, 730 and 732, 731 and 733, 732 and 734, 733 and 735, 734 and 736, 735 and 737, 736 and 738, 737 and 739, 738 and 740, 739 and 741, 740 and 742, 741 and 743, 742 and 744, 743 and 745, 744 and 746, 745 and 747, 746 and 748, 747 and 749, 748 and 750, 749 and 751, 750 and 752, 751 and 753, 752 and 754, 753 and 755, 754 and 756, 755 and 757, 756 and 758, 757 and 759, 758 and 760, 759 and 761, 760 and 762, 761 and 763, 762 and 764, 763 and 765, 764 and 766, 765 and 767, 766 and 768, 767 and 769, 768 and 770, 769 and 771, 770 and 772, 771 and 773, 772 and 774, 773 and 775, 774 and 776, 775 and 777, 776 and 778, 777 and 779, 778 and 780, 779 and 781, 780 and 782, 781 and 783, 782 and 784, 783 and 785, 784 and 786, 785 and 787, 786 and 788, 787 and 789, 788 and 790, 789 and 791, 790 and 792, 791 and 793, 792 and 794, 793 and 795, 794 and 796, 795 and 797, 796 and 798, 797 and 799, 798 and 800, 799 and 801, 800 and 802, 801 and 803, 802 and 804, 803 and 805, 804 and 806, 805 and 807, 806 and 808, 807 and 809, 808 and 810, 809 and 811, 810 and 812, 811 and 813, 812 and 814, 813 and 815, 814 and 816, 815 and 817, 816 and 818, 817 and 819, 818 and 820, 819 and 821, 820 and 822, 821 and 823, 822 and 824, 823 and 825, 824 and 826, 825 and 827, 826 and 828, 827 and 829, 828 and 830, 829 and 831, 830 and 832, 831 and 833, 832 and 834, 833 and 835, 834 and 836, 835 and 837, 836 and 838, 837 and 839, 838 and 840, 839 and 841, 840 and 842, 841 and 843, 842 and 844, 843 and 845, 844 and 846, 845 and 847, 846 and 848, 847 and 849, 848 and 850, 849 and 851, 850 and 852, 851 and 853, 852 and 854, 853 and 855, 854 and 856, 855 and 857, 856 and 858, 857 and 859, 858 and 860, 859 and 861, 860 and 862, 861 and 863, 862 and 864, 863 and 865, 864 and 866, 865 and 867, 866 and 868, 867 and 869, 868 and 870, 869 and 871, 870 and 872, 871 and 873, 872 and 874, 873 and 875, 874 and 876, 875 and 877, 876 and 878, 877 and 879, 878 and 880, 879 and 881, 880 and 882, 881 and 883, 882 and 884, 883 and 885, 884 and 886, 885 and 887, 886 and 888, 887 and 889, 888 and 890, 889 and 891, 890 and 892, 891 and 893, 892 and 894, 893 and 895, 894 and 896, 895 and 897, 896 and 898, 897 and 899, 898 and 900, 899 and 901, 900 and 902, 901 and 903, 902 and 904, 903 and 905, 904 and 906, 905 and 907, 906 and 908, 907 and 909, 908 and 910, 909 and 911, 910 and 912, 911 and 913, 912 and 914, 913 and 915, 914 and 916, 915 and 917, 916 and 918, 917 and 919, 918 and 920, 919 and 921, 920 and 922, 921 and 923, 922 and 924, 923 and 925, 924 and 926, 925 and 927, 926 and 928, 927 and 929, 928 and 930, 929 and 931, 930 and 932, 931 and 933, 932 and 934, 933 and 935, 934 and 936, 935 and 937, 936 and 938, 937 and 939, 938 and 940, 939 and 941, 940 and 942, 941 and 943, 942 and 944, 943 and 945, 944 and 946, 945 and 947, 946 and 948, 947 and 949, 948 and 950, 949 and 951, 950 and 952, 951 and 953, 952 and 954, 953 and 955, 954 and 956, 955 and 957, 956 and 958, 957 and 959, 958 and 960, 959 and 961, 960 and 962, 961 and 963, 962 and 964, 963 and 965, 964 and 966, 965 and 967, 966 and 968, 967 and 969, 968 and 970, 969 and 971, 970 and 972, 971 and 973, 972 and 974, 973 and 975, 974 and 976, 975 and 977, 976 and 978, 977 and 979, 978 and 980, 979 and 981, 980 and 982, 981 and 983, 982 and 984, 983 and 985, 984 and 986, 985 and 987, 986 and 988, 987 and 989, 988 and 990, 989 and 991, 990 and 992, 991 and 993, 992 and 994, 993 and 995, 994 and 996, 995 and 997, 996 and 998, 997 and 999, 998 and 1000, 999 and 1001, 1000 and 1002, 1001 and 1003, 1002 and 1004, 1003 and 1005, 1004 and 1006, 1005 and 1007, 1006 and 1008, 1007 and 1009, 1008 and 1010, 1009 and 1011, 1010 and 1012, 1011 and 1013, 1012 and 1014, 1013 and 1015, 1014 and 1016, 1015 and 1017, 1016 and 1018, 1017 and 1019, 1018 and 1020, 1019 and 1021, 1020 and 1022, 1021 and 1023, 1022 and 1024, 1023 and 1025, 1024 and 1026, 1025 and 1027, 1026 and 1028, 1027 and 1029, 1028 and 1030, 1029 and 1031, 1030 and 1032, 1031 and 1033, 1032 and 1034, 1033 and 1035, 1034 and 1036, 1035 and 1037, 1036 and 1038, 1037 and 1039, 1038 and 1040, 1039 and 1041, 1040 and 1042, 1041 and 1043, 1042 and 1044, 1043 and 1045, 1044 and 1046, 1045 and 1047, 1046 and 1048, 1047 and 1049, 1048 and 1050, 1049 and 1051, 1050 and 1052, 1051 and 1053, 1052 and 1054, 1053 and 1055, 1054 and 1056, 1055 and 1057, 1056 and 1058, 1057 and 1059, 1058 and 1060, 1059 and 1061, 1060 and 1062, 1061 and 1063, 1062 and 1064, 1063 and 1065, 1064 and 1066, 1065 and 1067, 1066 and 1068, 1067 and 1069, 1068 and 1070, 1069 and 1071, 1070 and 1072, 1071 and 1073, 1072 and 1074, 1073 and 1075, 1074 and 1076, 1075 and 1077, 1076 and 1078, 1077 and 1079, 1078 and 1080, 1079 and 1081, 1080 and 1082, 1081 and 1083, 1082 and 1084, 1083 and 1085, 1084 and 1086, 1085 and 1087, 1086 and 1088, 1087 and 1089, 1088 and 1090, 1089 and 1091, 1090 and 1092, 1

haplotype block which is adjacent to a polymorphism.

18. The method of claim 17, wherein the primer to be used for said primer extension assay has the sequence as set forth in SEQ ID NO: 9, 10, 11 or 12.
19. The method of any one of claims 12 to 16, wherein said differential hybridization assay or said assay detecting allele-specific enzyme cleavage uses probes which hybridize specifically with a portion of said haplotype block which comprises a polymorphism.
20. The method of claim 19, wherein said probes have the sequence as set forth in SEQ ID NO: 13 and 14; 15 and 16; 17 and 18; or 19 and 20.
21. The method of any one of claims 1 to 7, wherein the expression level to be determined is the mRNA expression level.
22. The method of any one of claims 1 to 7, wherein the expression level to be determined is the protein expression level.
23. The method of any one of claims 2, 4 or 8 to 22, further comprising the step of treating said patient suffering from depression with an antidepressant.
24. A pharmaceutical composition comprising
 - (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451;
 - (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451; and/or
 - (c) a polypeptide encoded by the nucleic acid of (a) or (b).
25. Use of
 - (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451;

- (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451;
- (c) a polypeptide encoded by the nucleic acid of (a) or (b);
- (d) an activator of the expression of the polypeptide with the sequence of SwissProt accession number Q13451; and/or
- (e) an activator of the polypeptide with the sequence of SwissProt accession number Q13451
for the manufacture of a pharmaceutical composition for the treatment of depression.
26. A method of treating depression comprising the administration of
- (a) a nucleic acid encoding a polypeptide with the sequence of SwissProt accession number Q13451;
- (b) a nucleic acid hybridizing to the complementary strand of the nucleic acid of (a) and encoding a polypeptide having the biological activity of the polypeptide with the sequence of SwissProt accession number Q13451;
- (c) a polypeptide encoded by the nucleic acid of (a) or (b);
- (d) an activator of the expression of the polypeptide with the sequence of SwissProt accession number Q13451; and/or
- (e) an activator of the polypeptide with the sequence of SwissProt accession number Q13451
to a patient suffering from depression.
27. Use of
- (a) geldanamycin or a geldanamycin derivative that can disrupt and inhibit the association between FKBPO2 and Hsp90; and/or

28. A method of treating depression comprising the administration of
 - (a) geldanamycin or a geldanamycin derivative that can disrupt and inhibit the association between FKBP52 and Hsp90; and/or
 - (b) an antibody or an aptamer specifically recognizing FKBP52 or a fragment or epitope thereofto a patient suffering from depression.

Abstract

EPO - Munich
33
25 Nov. 2003

The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to antidepressant therapy. Furthermore, a method of developing an anti-depressant drug, and pharmaceutical compositions are provided.

EPO - Munich,
33
25 Nov. 2003





Figure 1

Association with response at 2 weeks

Association of rs1360780 SNP with antidepressant response





Figure 3







Figure 5

6/9

Association of rs 3800372 with response



Association of rs3800372 with number of depressive episodes




Figure 7

FKBP51 protein levels for rs3800372 SNP






Figure 9

SEQUENCE LISTING

EPO - Muni
33
25 Nov. 2643

```

<110> Max-Planck-Institut für Psychiatrie
      Binder, Elisabeth
      Holsboer, Florian
      Rein, Theo
      Wochnik, Gabriele
      Müller-Myhsok, Bertram
      Uhr, Manfred

<120> FKBP51: A Novel Target for Antidepressant Therapy

<130> H 2589 EP

<160> 20

<170> PatentIn version 3.1

<210> 1
<211> 30
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 1
      acgttggatg tatctggcaa ccctaacctc          30

<210> 2
<211> 30
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 2
      acgttggatg cctaacgaga tagtgaggag          30

<210> 3
<211> 30
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 3
      acgttggatg aacaccaaga gaagcagctc          30

```

```
<210> 4
<211> 30
<212> DNA
<213> artificial sequence

<220>
<221> source

<223> /note="Description of artificial sequence: oligonucleotide"
<400> 4
acgttggatg ctatccacct cctccataag
```

30

```
<210> 5
<211> 30
<212> DNA
<213> artificial sequence

<220>
<221> source

<223> /note="Description of artificial sequence: oligonucleotide"

<400> 5
acgttggatg aagagatcca ggcacacagaag
```

30

```
<210> 6
<211> 30
<212> DNA
<213> artificial sequence

<220>
<221> source

<223> /note="Description of artificial sequence: oligonucleotide"

<400> 6
acgttggatg tgccagcagt agcaagtaag
```

30

```

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 8
acgttggatg tttacactcc tctatcatgc                                30

<210> 9
<211> 19
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 9
gactcctaca ttttcctct                                19

<210> 10
<211> 18
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 10
gaaggcagctc cctttaga                                18

<210> 11
<211> 22
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 11
ggctttcaca taagcaaagt ta                                22

<210> 12
<211> 24
<212> DNA
<213> artificial sequence

<220>
<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 12
aagagcaact atttatttgt caac                                24

```

```
<210> 13
<211> 21
<212> DNA
<213> artificial sequence

<220>
<221> source

<223> /note="Description of artificial sequence: oligonucleotide"

<400> 13
attttcctct atcttggtcc a
```

21

```
<210> 14
<211> 21
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 14
attttccctct gtcttggtcc a
```

21

```
<210> 15
<211> 21
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 15
taaagttaatt ctctaaaggg a
```

21

```
<210> 16
<211> 21
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<100> 16
XXXXXXXXXX
```

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 17
agcaaagtta tacaaaacaa a

21

<210> 18
<211> 21
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 18
agcaaagtta cacaaaacaa a

21

<210> 19
<211> 21
<212> DNA
<213> artificial sequence

<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 19
atttgtcaac cctacagatt t

21

<210> 20
<211> 21
<212> DNA
<213> artificial sequence


<220>

<221> source
<223> /note="Description of artificial sequence: oligonucleotide"

<400> 20
atttgtcaac actacagatt t

21

PCT/EP2004/010857



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.